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ABSTRACT 
In fibroblasts, transforming growth factor β-1 (TGFβ1) signals via canonical and non-
canonical pathways to promote wound healing or hyper-contractile responses resulting in 
scars. The oral cavity however does not scar and fibrotic responses such as gingival 
hyperplasia are characterized by a hyper-proliferative response. The involvement of non-
canonical, TGFβ-activated kinase-1 (TAK1) - mediated TGFβ1 signaling in gingival 
fibroblasts has not been previously examined. Here I show that TAK1 selective inhibitor 
(5Z)-7-Oxozeaenol blocks TGFβ1-induced expression of wound healing and fibrotic marker 
CCN2 (connective tissue growth factor) in gingival fibroblasts. Genome-wide expression 
profiling revealed that essentially all TGFβ1 induced genes were in fact sensitive to TAK1 
inhibition in gingival fibroblasts (139/147) including those involved in proliferative and 
wound healing responses. This data was confirmed using RT-qPCR to detect mRNA 
expression as well as functional cell proliferation assay. (5Z)-7-Oxozeaenol might be 
investigated in the treatment of gingival hyperplasia in the future.  
 
 
 
 
 
 
 
 
KEYWORDS: TGFβ1; TAK1; (5Z)-7-Oxozeanol; fibrosis; wound healing; CCN2; gingival 
fibroblasts; proliferation 
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1.1 Overview of physiological wound healing 
Disruption or damage of the anatomical structure and function of a tissue or organ 
is characterized as a wound (Lazarus et al., 1994; Robson et al., 2001). Wound healing is 
an orderly physiological process in all tissues and organs of the body in response to 
injury, with the goal of anatomical and functional restoration of that tissue or organ (Guo 
and DiPietro, 2010; Velnar et al., 2009). Aside from the liver, eye and skeletal tissues, 
this process of repair is generally conserved across various tissues and organs and has 
been described as having four phases: hemostasis/coagulation, inflammation, 
proliferation and resolution/remodeling (Guo and DiPietro, 2010; Hunt et al., 2000; 
Robson et al., 2001; Velnar et al., 2009; Wynn 2008). It has been hypothesized that 
failure to terminate the repair program leads to excessive deposition of connective tissue 
in place of the normal parenchyma resulting in the development of fibrotic scars (Guo 
and DiPietro, 2010; Leask 2008; Wynn 2008). Interestingly, in contrast to every other 
adult tissue, the oral cavity does not scar in response to injury (Egusa et al., 2010; Guo et 
al., 2011a, 2011b; Schor et al., 1996; Wikesjo et al., 1992). Understanding the differences 
in wound healing responses among different tissue types is of importance for future 
clinical benefit (Ebisawa et al., 2011; Eslami et al., 2009; Guo et al., 2011a, 2011b; Schor 
et al., 1996). At present however, relatively little is known about the fundamental 
mechanisms underlying scarless repair in the gingiva, thus the discussion of wound 
healing and fibrotic mechanisms in the gingiva are best considered in the context of 
dermal repair. What is currently known about cutaneous and gingival tissue repair, 
fibrosis and structural anatomy are thus compared and discussed below.                       . 
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1.2 Comparative anatomy: structure of skin and gingiva  
1.2.1 Structural anatomy of skin  
Skin, the largest organ of the body is comprised of three layers: the epidermis, 
dermis and hypodermis (Wolff et al., 2007) (Figure. 1.1). The epidermis, composed of 
keratinized stratified squamous epithelium is of ectodermal origin (Wolff et al., 2007). 
Depending on the thickness of the skin, the epidermis consists of five (thick skin: palms, 
soles) or four (thin skin) outermost to innermost layers: stratum corneum, stratum 
lucidum (in thick skin only), stratum granulosum, stratum spinosum and stratum basale 
(Vi 2010; Wolff et al., 2007). Analogous to the skin, the superficial layer of the gingiva is 
comprised primarily of keratinocytes with occasional melanocytes, Langerhans’ cells 
(antigen presenting cells) and neurosensory cells. It is further classified into four sub-
layers similarly to skin: stratum corneum, stratum granulosum, stratum spinosum and 
stratum basale (Nanci, 2013; Squier and Kremer, 2001). Differentiation of keratinocytes 
as they move from the deep (stratum basale) to superficial (stratum granulosum) layers 
constitutes the squamous appearance of the layer, resulting in keratin squames which are 
shed in the stratum corneum (Nanci, 2013; Squier and Kremer, 2001; Thomson, 2012). 
Dermis, mesodermal in origin, is a strong and flexible connective tissue layer 
below the epidermis and above the hypodermis which is composed of loose connective 
and fatty tissues (Gosain et al., 2004; Harper and Grove, 1979; Montagna and Parakkal, 
1974; Wolff et al., 2007). Fibroblasts, macrophages, mast cells, extracellular matrix 
(ECM) (types I and III collagen, elastin and fibronectin, proteoglycans), glycoproteins, 
nerve fibers and blood vessels are found within the dermis (Gosain et al., 2004; 
Palaiologou et al., 2001). The dermis is further subdivided into papillary and reticular 
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Figure 1.1. Comparative anatomy: Structure of (A) skin and (B) gingival 
masticatory mucosa in cross section. Epithelium layer is the outermost layer of the 
gingival masticatory mucosa while the outermost layer in the skin is known as the 
epidermis. The dermis (skin) or lamina propria (gingiva) are the connective tissue layers 
below the outermost layer. (A) Reprinted from: Kendall AC, Nicolaou A. 2013. Bioactive 
lipid mediators in skin inflammation and immunity. Progress in Lipid Research. Volume 
52, Issue 1, pages 141–164 with permission from Elsevier.  
http://dx.doi.org/10.1016/j.plipres.2012.10.003 
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sub-layers in the superficial to deep order. The former forms ridges at the point of contact 
with the epidermis and contains thin, poorly organized collagen fibers and higher 
collagen type III to type I ratio as well as many more fibroblasts, which show higher 
proliferation and enzymatic activity (Gosain et al., 2004; Harper and Grove, 1979; 
Montagna and Parakkal, 1974; Vi 2010; Weber et al., 1984). The reticular region, located 
above the hypodermis, is characterized by a decreased collagen type III to type I ratio, 
thick and organized collagen fibers and fibroblasts that show reduced proliferation 
capacity yet increased contractile responses (Harper and Grove, 1979; Vi 2010; Weber et 
al., 1984). Hair follicles as well as sweat and sebaceous glands are also found within the 
dermis.       
1.2.2 Structural anatomy of gingiva 
Gingival tissue is classified as the oral mucosa surrounding the tooth which acts 
as a protective barrier (mechanical damage and environmental factors) for the underlying 
tissues (Nanci, 2013; Seoane Leston et al., 2002; Squier and Kremer, 2001). Gingival 
mucosa which faces the oral cavity is further known as masticatory mucosa. The 
epithelial and connective tissue layers of gingiva are organized in a similar fashion to that 
of the skin. Masticatory mucosa is comprised of the superficial keratinized stratified 
squamous epithelium layer which is supported by the underlying lamina propria layer, 
analogous to the dermis layer of the skin (Nanci, 2013; Squier and  Kremer, 2001; 
Thomson, 2012). The basal lamina further forms the interface between the two layers 
(Nanci, 2013; Squier and Kremer, 2001; Thomson, 2012) (Figure 1.1). Located below 
the lamina propria, the submucosal region in the gingiva is analogous to the hypodermis 
layer of the skin (Nanci, 2013; Squier and Kremer, 2001; Thomson, 2012). The lamina 
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propria is organized in a similar fashion to the dermis. Conversely, unlike skin, gingival 
masticatory mucosa lacks hair follicles as well as sweat and sebaceous glands (Seoane 
Leston et al., 2002).  
1.3 Pathological wound healing: overview of fibrosis 
Wound healing can be affected by multiple factors, generally characterized as 
local (pertaining to the wound itself) or systemic (pertaining to the overall health of the 
organism) (Guo and DiPietro, 2010). Simultaneous processes of inflammation, tissue 
remodeling and regeneration serve as indicators of fibrotic disease, loosely defined by a 
time-dependent increase of total collagen deposition which exceeds the rate of collagen 
degradation (Wynn, 2008). The excessive production, remodeling and contraction of the 
ECM further leads to excessive scarring, the hallmark feature of fibrotic diseases (Krieg 
et al., 2007; Leask 2008). The resulting fibrotic scars exhibit a reduction in original 
elasticity of the tissue, are fairly acellular and replace normal tissue architecture while 
diminishing its function (Singer and Clark, 1999; Toriseva et al., 2007). It is estimated 
that close to 45% of deaths in developed countries are attributed to some form of the 
disease condition which affects the function of multiple organs (Pinzani 2008; Wynn 
2008). Fibrotic diseases are also the largest group of diseases to which there is no 
established therapy (Leask 2008; Pinzani 2008; Wynn 2008). Diabetic nephropathy, 
pulmonary fibrosis, liver cirrhosis, atherosclerosis, systemic sclerosis/scleroderma, 
gingival hyperplasia and even hypertension are some of the numerous examples of 
fibrotic diseases affecting individual organs as well as the entire organism (Leask 2008, 
2011; Pinzani 2008). 
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Although fibrosis is a complex disease involving many mediators, it is thought 
that myofibroblasts, fibroblast-like contractile cells, as well as three main extracellular 
factors TGFβ1, endothelin-1 and CCN2 (connective tissue growth factor) represent a 
common mechanism underlying the onset and progression of fibrosis (Krieg, et al., 
2007).  
1.3.1 Fibrotic lesions contain abundant myofibroblasts  
The cell type responsible for persistent fibrosis is the myofibroblast, a contractile 
and secretory cell which is characterized by the increased intracellular staining for α-
Smooth Muscle Actin (α-SMA),  incorporated into stress fibers that span the length of the 
cell (Gabbiani 2003). α-SMA is a contractile protein which attaches to the ECM through 
fibronexus/focal adhesion structures (the in vivo and in vitro junction respectively) on the 
cell surface and promotes the excessive adhesion and mechanical force generation at the 
site of wounding, thus promoting wound closure and scar formation  (Hinz, 2006, 2007, 
2010; Hinz and Gabbiani, 2003; Hinz et al., 2007; Krieg et al., 2007; Shi-wen et al., 
2012). Focal adhesions, composed of actin filaments, act as a link between the contractile 
α-SMA protein inside the cell and the ECM outside (Hinz and Gabbiani, 2003; Liu et al., 
2009; Parsons, 2003, Tomasek, et al., 2002). They contain two other important 
components: integrins (the cell surface receptors for ECM) and focal adhesion kinase 
which promotes adhesive signaling responses and subsequent fibrosis (Chen et al., 2005; 
Hinz and Gabbiani, 2003; Liu et al., 2009; Mimura et al., 2005; Parsons 2003; Tomasek, 
et al., 2002). Essentially, the myofibroblast phenotype in vitro and in vivo is characterized 
by the appearance of a contractile cytoskeleton accompanied by the de novo expression 
of α-SMA positive stress fibers, integrin attachments to the ECM, replacement of N-
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cadherin adhesions with the formation of bigger OB-cadherin (cadherin-11)-type cell-cell 
adhesions as well as the formation of large, so–called “supermature” focal adhesions  
(Figure 1.2) (Hinz 2007, 2010; Hinz et al., 2004).   
Increased myofibroblast numbers in the dermis correlate with the excessive 
production of collagen and other ECM components, contraction of ECM and granulation 
tissue formation (Hinz and Gabbiani, 2003; Hinz et al., 2007; Krieg et al., 2007; 
Tomasek, et al., 2002). Increased myofibroblast numbers in the skin of systemic sclerosis 
patients also directly correlates with the extent of local collagen deposition and the 
Rodnan skin score — which measures the extent of scarring and disease progression 
(Hinz et al., 2012; Kissin, et al., 2006; Krieg et al., 2007).  
In physiological wound healing, myofibroblasts begin their regression and 
undergo apoptosis with the onset of wound re-epithelialization. In contrast, during 
fibrosis myofibroblasts persist, resulting in the excessive production and remodeling of 
the ECM (Desmoulière et al., 1995; Hinz et al., 2012; Krieg et al., 2007). 
1.3.2 Origin of myofibroblasts  
Several theories have been proposed relating to the origin of myofibroblasts, 
possibly the earliest point of control in fibrotic disease progression and most accurate 
indication of the onset of fibrosis (Figure 1.2) (Hinz et al., 2007; 2012; Krieg et al., 
2007). For example, the dermal myofibroblasts that are detected in response to wound 
healing and/or scleroderma have been purported to arise as a result of: 1) differentiation 
of resident dermal fibroblasts via signaling in response to growth factors  such as TGFβ1; 
2) recruitment of circulating fibrocytes, bone marrow (BM)-derived circulating cells or   
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              Copyright © Elsevier. American Society for Investigative Pathology.  
Figure 1.2. Myofibroblast characterization and possible origins. Although several 
theories have been proposed relating to possible myofibroblast progenitors, fibroblast to 
myofibroblast differentiation (driven by TGFβ1) is considered to be a predominant 
source of myofibroblasts in wound healing and fibrosis. Expression of adherens 
junctions, super-mature focal adhesions and α-SMA incorporation into stress fibers are 
indicative of myofibroblast phenotype. (Adapted with permission from Figure 2. One 
cell, multiple origins. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, 
Gabbiani G. 2007. The myofibroblast: one function, multiple origins. Am J Pathol. 2007 
Jun;170(6):1807-16. DOI: 10.2353/ajpath.2007.070112; http://www.elsevier.com) 
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resting mesenchymal precursor cells to the specific tissue site and subsequent 
differentiation into myofibroblasts via induction by cell-ECM contacts or cytokines; 3) 
activation of vascular pericytes and smooth muscle cells concomitant with the repair of 
damaged vasculature in response to injury or 4) clonal selection of resting myofibroblasts 
(Abe et al., 2001; Direkze et al., 2003; Hinz et al., 2001, 2007; Krieg et al., 2007; 
Rajkumar et al., 2005).  
Of interest still is the traditional view of fibroblast to myofibroblast 
differentiation, likely to be the predominant process in physiological wound healing and 
repair. This connective tissue repair process is primarily driven by fibroblasts which are 
resident connective tissue cells. These cells differentiate into a contractile myofibroblast 
phenotype in response to mechanical tension and growth factors such as TGFβ1 (Hinz 
2007, 2010; Krieg et al., 2007; Leask 2008). 
1.4 Fibroblast cells   
Fibroblasts are connective tissue cells of mesodermal origin, loosely defined as 
cells of “spindle shape” capable of forming an extracellular matrix rich in type I and/or 
type III collagen, adhering to ECM and lacking markers for other cell lineages (Alberts et 
al., 1994; Chang, et al., 2002; Ebisawa et al., 2011). They are the most versatile 
connective tissue cell type which can be classified as Loose (in adipose tissue), Fibrous 
(in tendons, ligaments and cartilage) and Specialized (in bone and blood) that together 
create a structural framework of body architecture (Alberts et al., 1994). Certain so-called 
“immature” fibroblasts (sometimes referred to as mesenchymal cells) from various body 
regions are capable of differentiating into other connective tissue cell types, often co-
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existing in a mixed population with the mature fibroblasts (Alberts et al., 1994; Egusa et 
al., 2010).  
Fibroblasts are considered essential for the wound healing process (Abe et al., 
2001). Deficiency in fibroblast proliferation and wound closure leads to ulceration. 
Conversely, abnormal proliferation and/or differentiation into myofibroblasts lead to the 
excessive production of collagen and other ECM proteins as well as contraction of ECM 
resulting in fibrosis (Krieg et al., 2007; Leask, 2008).  
1.4.1 Fibroblast to myofibroblast differentiation  
Growth factors such as TGFβ1, biomechanical tension and matrix signaling are 
three known factors required for fibroblast to myofibroblast differentiation (Gabbiani 
2003; Lagares et al., 2012; Tomasek et al., 2002). Importantly, the disruption of the 
architecture and composition of ECM, which normally acts as a stress shield for the 
resident fibroblasts, leads to fibroblast activation and migration into the wound site (Hinz 
2007; Hinz et al., 2007; Tomasek et al., 2002; Werner and Grose, 2003).  
1.5 The role of TGFβ1 in wound healing and fibrosis 
TGFβ1 was first identified in 1983 and has been characterized as a member of 
TGFβ superfamily which also includes Nodals, Inhibins, Activins, Bone Morphogenetic 
Protein (BMP), Growth and Differentiation Factor (GDF), Mullerian inhibitory substance 
(MIF) as well as the two remaining TGFβ isoforms: TGFβ2 and TGFβ3 (Assoian et al., 
1983; Barrientos et al., 2008; Kingsley 1994; Rahimi and Leof 2007). The three TGFβ 
isoforms are predominantly expressed by macrophages, endothelial, fibroblasts and 
epithelial cells at the site of the injured skin (Barrientos et al., 2008; Rahimi and Leof, 
2007). Both covalent and non-covalent interactions of mature TGFβ polypeptide with the 
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latency associated peptide (LAP) or other latent TGFβ-binding proteins renders it 
inactive (Leask 2008; Munger et al., 1997; Rahimi and Leof, 2007). Upon cellular 
secretion, these latent TGFβ-binding proteins and/or LAP are removed by proteolysis, 
allowing for the formation of an active 25kDa TGFβ dimer which initiates signaling 
responses by interacting with the type II/type I (activin receptor-like kinase, ALK)/TGFβ 
heteromeric receptor complex comprised of one of the five and seven distinct receptor 
types respectively (Leask 2008; Rahimi and Leof, 2007). Type III (betaglycan) and type 
V (IGFBP-3R/LRP-1) receptors may be further utilized in conjunction to the type I and 
type II receptor activation (Blobe et al., 2001; Eickelberg et al., 2002; Huang et al., 2003; 
Leal et al., 1997, 1999; Liu et al., 1994, 1997; O’Grady et al., 1991, 1992). ALK5 
however is the most frequently utilized TGFβ type I receptor in fibroblast cells (Leask, 
2008; Rahimi and Leof, 2007).  
TGFβ1 participates in all stages of the physiological wound healing with 
increases in its expression shortly after the onset of injury (Barrientos et al., 2008). 
During the remodeling phase of wound healing, increases in the expression of tissue 
inhibitor of metalloproteinases (TIMPs), collagen type I and III as well as decreases in 
the expression of matrix metalloproteinases (MMP) MMP-1, MMP-3, and MMP-9 are 
mediated by TGFβ1 signaling (Barrientos et al., 2008). Additional responses include 
facilitation of wound contraction and closure by myofibroblasts, up-regulation of 
fibronectin, collagen, fibronectin and integrin receptors and protease inhibitors as well as 
recruitment of inflammatory cells to the site of injury during the earlier stages of wound 
healing (Barrientos et al., 2008; Clark 1996; Mauviel  et al., 1996; Meckmongkol et al., 
2007; Papakonstantinou et al., 2003; Zeng et al., 1996).  
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Fibroblast activation in response to TGFβ1 involves two separate, Smad-
dependent and Smad-independent pathways, also known as the canonical and non-
canonical pathways, respectively (Bhattacharyya et al., 2008; Leask 2006, 2008; Leask 
and Abraham, 2004; Massague 1998; Mehra and Wrana, 2002; Rahimi and Leof, 2007) 
(Figure 1.3). 
 1.5.1 Canonical TGFβ1 signaling in fibroblasts  
Canonical, Smad-dependent TGFβ1 signaling in cells such as fibroblasts involves 
binding of TGFβ1 ligand to the type II/type I TGFβ receptor heteromer and activation of 
downstream Smad complexes, transcription factors which mediate the expression of 
collagen and other pro-fibrotic genes (Leask 2008; Massague 1998; Rahimi and Leof, 
2007) (Figure 1.3). The Smad family of transcriptional co-regulators includes eight 
different Smad isoforms distributed among three sub-classes and utilized by different 
members of the TGFβ family (Rahimi and Leof 2007). Smad 2 and 3 generally are 
activated by TGFβ, Activin and Nodal members of the TGFβ superfamily; Smad 1, 5 and 
8 are activated  by MIS, BMP and GDF whereas the inhibitory Smads;  Smad 6 and 7 act 
as negative regulators of BMP and TGFβ/Activin/BMP pathways, respectively (Goumans 
et  al., 2002; Rahimi and Leof 2007; Trojanowska, 2009). Interestingly, the negative 
regulators Smad 6 and Smad 7 are similarly transcribed via SBE activity upon TGFβ 
stimulation, thus regulating its own expression and TGFβ signaling in a negative 
feedback loop (Leask, 2008; Lin et al., 2003). Finally, in scleroderma fibroblasts, Smad 1 
is involved in TGFβ-mediated signaling where the presence of both TGFβ and CCN2 
drive Smad 1 phosphorylation and the subsequent increase in CCN2 production in a 
positive feedback loop (Pannu et al., 2007; Trojanowska, 2009).  
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Figure 1.3. TGFβ1 signaling in fibroblasts. Canonical and non-canonical signaling 
pathways are outlined (General and Gene-Specific pathways respectively). TGFβ1 
initiates signaling responses by interacting with the type II/type I TGFβ heteromeric 
receptor complex, resulting in Smad3/Smad4 activation, translocation to the nucleus and 
transcription of target genes by binding to the CAGA consensus sequence of Smad-
binding DNA elements (SBE). Alternatively, TGFβ1 signals via integrin/syndecan4 
receptors synergistically with CCN2 for additional, tissue and context specific regulation. 
(Adapted with permission from Figure 2. Leask A. 2006. Scar wars: is TGFβ the 
phantom menace in scleroderma? Arthritis Res Ther. 2006; 8(4): 213. Doi: 
10.1186/ar1976. BioMed Central is the original publisher).       
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Considering the canonical signaling pathway, TGFβ1 binds to the type II TGFβ 
receptor leading to the recruitment of type I (ALK5) TGFβ1 receptor. ALK5 becomes 
phosphorylated at its glycine-serine rich domain, and phosphorylates Smad 2/3 complex 
at the C terminal Ser-Ser-X-Ser (SSXS) motif leading to dissociation of Smad 2/3 
complex from the receptor and its subsequent association with the common mediator 
Smad 4 (Derynck and Zhang, 2003; Leask 2008, Massague et al., 2005; Rahimi and Leof, 
2007; Sporn and Jakowlew, 2010). Additional adaptor proteins including SARA (Smad 
anchor for receptor activation), HRS/HGS (hepatocyte growth factor-regulated tyrosine 
kinase substrate) and cPML may be recruited to facilitate ALK5-dependent 
phosphorylation of Smads (Lin et al., 2004; Miura et al., 2000; Rahimi and Leof 2007; 
Tsukazaki et al., 1998). p300/CBP co-activators may further assist in the Smad-
dependent gene activation and Fast-1 nuclear DNA binding protein is necessary for 
Smad2 DNA interaction (Ghosh and Varga 2007; Leask, 2008; Liu et al., 1999; Zhou et 
al., 1998).  
Nuclear translocation of Smad 2/3-Smad 4 trimer complex and direct interaction 
of Smad 3/4 with the GC rich sequences of  certain promoters as well as the 
GTCT/CAGA consensus sequence of Smad-binding DNA elements (SBE) leads to 
expression of  collagen alpha-2(I) chain and other profibrotic genes (Bhattacharyya et al., 
2008; Derynck and Zhang, 2003; Massague et al., 2005; Rahimi and Leof, 2007) 
 1.5.2 Targeting canonical TGFβ1 signaling in fibrosis disease treatment   
TGFβ1 signaling in fibroblasts induces both fibroblast proliferation and 
differentiation into myofibroblast as well as ECM synthesis, connective tissue deposition 
and contraction (Grotendorst et al., 2004; Guo et al., 2012; Leask 2008; Rahimi and Leof, 
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2007). However, signaling via members of the TGFβ superfamily is known to be 
involved with multiple physiological and cellular processes including 
immunosuppression, cell differentiation, proliferation (mesenchymal cells), migration, 
growth inhibition (epithelial, endothelial, hematopoietic and neuronal cells, murine                                                               
embryonic fibroblasts) or apoptosis (Figure 1.4). (Datto et al., 1999; Grotendorst et al., 
2004; Guo et al., 2012; Leask 2008; Rahimi and Leof, 2007; Roberts et al.,1986). 
Interestingly, a great number of these distinct cellular responses are mediated via the 
canonical signaling pathway, often involving identical TGFβ-Smad family signaling 
participants (Rahimi and Leof, 2007). However, the canonical TGFβ1 signaling pathway 
does not mediate CCN2/CTGF or α-SMA expression in scleroderma fibroblasts (Chen et 
al., 2006; Holmes et al, 2001). Aside from fibroblasts, TGFβ1 is also produced and 
locally secreted by macrophages and other cell types and exhibits a profibrotic or 
suppressive role depending on the cell type (Rahimi and Leof, 2007; Wynn 2008).  
The fibrogenic phenotype arising from fibroblast exposure to TGFβ1 is non-
heritable and persists only in the presence of TGFβ1 polypeptides, suggesting the 
removal of “excess” TGFβ1 is sufficient to revert cells to their previous physiologic state 
(Leask, 2008; McWhirte et al., 1994). TGFβ-deficient mouse models exhibit systemic 
tissue necrosis, organ failure and death (Kulkarni et al., 1993). In contrast, murine models 
with TGFBR1 (ALK5) deletion die in utero, probably as a result of vascular defects 
incompatible with life (Carvalho et al., 2007; Larsson et al., 2001). Similarly, Smad3 
knock-out murine models develop emphysema, chronic inflammation and colorectal 
adenocarcinomas among other morbidities (Bonniaud et al., 2004a; Datto et al., 1999; 
Yang et al., 1999; Zhu et al., 1988). 
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Figure 1.4. The diverse, multifunctional, and pleiotropic effects of TGFβ. Signaling 
via TGFβ affects multiple cell types and cellular processes making it difficult to target 
TGFβ1 directly as a potential fibrotic disease treatment (Reproduced with permission of 
Oxford University Press from Figure 2. Bujak M, Frangogiannis NG. 2007. The role of 
TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 
May 1;74(2):184-95. Epub 2006 Oct 7; Doi:  10.1016/j.cardiores.2006.10.002) 
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Not surprisingly, studies that manipulate canonical TGFβ1 signaling pathways do not 
provide a specific point of interference which can be applied in future therapy of fibrotic 
diseases (Bonniaud et al., 2004; Denton et al., 2007; Evans, et al., 2003; Hu et al., 2003; 
Kulkarni et al., 1993; Leask et at., 2008; Shull et al., 1992). Further, the use of a 
recombinant human anti-TGFβ1 antibody (CAT-192) in a clinical trial for the treatment 
of early-stage diffuse cutaneous systemic sclerosis resulted in adverse side-effects 
including death without evidence of efficacy (Denton et al., 2007). Collectively, these 
observations suggest that examining non-canonical TGFβ signaling pathways, which may 
mediate specific cellular responses to TGFβ1, might be more target specific for the 
treatment of fibrosis.  
1.5.3 Non-canonical TGFβ1 signaling in fibroblasts 
Several Smad-independent, non-canonical TGFβ1 signaling pathways have been 
previously identified in fibroblasts (Leask 2008; Massague 1998; Rahimi and Leof, 2007; 
Verrecchia and Mauviel, 2007; Wynn 2008; Zhang 2009). These pathways cooperate 
with canonical TGFβ1 signaling, and tend to be gene and tissue specific (Figure 1.3). 
Non-canonical TGFβ1 signaling can involve the MEK/ERK, p38 or JNK MAP kinase 
(MAPK) pathways. For example,  TGFβ-dependent activation of Ras-MEK1-ERK1/2-
Elk-1 occurs via heparan sulfate-containing proteoglycan (HSPG) syndecan 4 as a co-
receptor (Barrientos et al., 2008; Chen et al., 2005; Massague et al., 2005; Verrecchia and 
Mauviel, 2007; Zhang 2009). Additional non-canonical signaling may involve Rho-like 
GTPase signaling pathways as well as phosphatidylinositol-3-kinase (PI3K)/AKT 
pathways (Zhang 2009). One example of the latter includes TGFβ-mediated activation of 
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p21 activated kinase 2 (PAK2) and Akt via PI3K intermediate (also an independent 
regulator) in fibroblasts (Rahimi and Leof, 2007; Wilkes et al., 2003; 2005).                 
1.6 TAK1 
TGF-β-activated kinase 1 (TAK1) mediates the ability of TGFβ1 to activate the 
p38 and JNK MAP kinase cascades (Guo et al., 2012; Shim et al., 2005, Shi-Wen et al., 
2009; Yamaguchi et al., 1995; Yamashita et al., 2008). This protein belongs to the 
mitogen-activated protein kinase kinase kinase (MAPKKK) family and was first 
identified in 1995 based on a screen of a murine cell line cDNA expression library (Shim 
et al., 2005; Yamaguchi et al., 1995). Activation of ectopic TAK1 in the MC3T3-E1 cell 
line following TGFβ treatment implicated this kinase in TGFβ1-mediated MAPK 
signaling, and established its name as TGFβ-activated kinase 1 (Yamaguchi et al., 1995).  
In humans, the 606 amino acid TAK1 protein sequence contains a unique 300 
amino acid C terminal region, as well as a putative N terminal domain resembling that of 
Raf-1 and MEKK  kinases (30% identity) (Wu et al., 2013; Yamaguchi et al., 1995). An 
ATP-driven protein kinase catalytic region lies at the junction between the two domains 
(Wu et al., 2013).  
TAK1-mediated signaling is activated in a number of cellular responses, 
including inflammation, apoptosis as well as certain cancers (Sakurai, 2012; Shim et al., 
2005; Yamashita et al., 2008). Aside from TGFβ signaling, tumor necrosis factor-α 
(TNF-α), interleukin 1-β (IL-1β) and Toll-Like receptor ligands use TAK1 as an 
intermediate in the activation of JNK/p38 and I-kappa B  kinases (IKK), as well as 
downstream transcription factors including Activator protein 1 (AP-1) and NF-kappaB 
(Guo et al., 2012; Shim et al., 2005; Shi-wen et al., 2009; Wang et al., 1997,2001; 
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Yamashita et al., 2008). TAK1 is therefore an important mediator of inflammatory 
responses (via NF-kappaB and AP-1 activation) (Shim et al., 2005; Shi-wen et al., 2009; 
Yamashita, et al., 2008). 
TAK1 has organ-specific effects. For example, TAK1 is essential for hepatic 
homeostasis. Loss of TAK1 from the liver using hepatocyte-specific Tak1-deficient 
(Tak1ΔHEP) mice resulted in inflammation, spontaneous hepatocyte death and 
perisinusoidal fibrosis developing at one month of age and eventually resulting in cancer 
(Inokuchi et al., 2010). Interestingly, tamoxifen-driven, global TAK1 deletion in mice 
conferred resistance to the development of renal fibrosis upon unilateral ureteric 
obstruction, resulting in reduced myofibroblast counts, collagen and pro-fibrotic gene 
expression due to abolished IL-1, TNF-α-induced JNK, p38, and NF-κB signaling 
attributed to TAK1 loss (Ma et al., 2011). 
1.6.1 TAK1- mediated non-canonical TGFβ1 signaling in fibroblasts 
In human and mouse fibroblasts, TGFβ1 activation of TAK1 results in the 
phosphorylation of stress-activated MAP kinase members JNK (via MKK4 intermediate) 
and Stress Activated Kinase p38 (via MKK6 or MKK3 intermediates) (Guo et al., 2012; 
Liu et al., 2007; Lovgren et al., 2011; Rahimi and Leof, 2007; Shibuya, et al., 1996; 
Thannickal et al., 2003; Wang et al., 1997, 2001; Yamaguchi  et al., 1995; Yamashita et 
al., 2008). TGFβ receptor-dependent phosphorylation of TAK1 is also known to involve 
HPK1 and/or TAB1/TAB2 adaptor proteins (Rahimi and Leof 2007; Shibuya et al., 1996; 
Wang, et al., 1997, 2001; Yamashita et al., 2008). Interestingly, TAB2 was found to be 
dispensable in regards to TGFβ induced gene expression and TAK1-mediated JNK 
signaling (Shim, et al., 2005). A study by Yamashita and colleagues in 2008 also 
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identified TNF-receptor-associated factor 6 (TRAF6) ubiquitin ligase as a direct link 
between the TGFβ receptor complex and TAK1, where the activated receptor complex 
leads to K63 polyubiquitination of TRAF6 which then mediates TAK1 activation by a yet 
unknown mechanism, possibly including TAK1/TAB2 complex formation and/or 
activation (Shim et al., 2005; Wang, et al., 2001; Yamashita et al., 2008). Activation of 
TAK1 through TGFβ1 receptor signaling is further thought to involve focal adhesion 
kinase: phosphorylation of TAK1 upon TGFβ1 stimulation was reduced either by pre-
treatment of wild-type fibroblasts with the FAK/Src inhibitor PP2, or in fibroblasts with 
FAK deletion (Shi-wen et al., 2009).  Canonical, Smad-mediated signaling was unaltered 
upon TAK1 deletion, consistent with the idea that TAK1 is a mediator of non-canonical 
TGFβ1 signaling (Shi-wen et al., 2009; Shim et al., 2005; Yamashita et al., 2008).  
1.6.2 Role of TAK1 in dermal homeostasis and wound repair 
The TAK1-JNK/p38 pathway has been previously shown to play an important 
role in adhesive, migratory, proliferative and contractile responses of dermal fibroblasts, 
as well as in fibroblast to myofibroblast differentiation in response to TGFβ1 (Guo et al., 
2012).  Much of what is known about the role of TAK1 in fibrosis comes from studies of 
dermal fibroblasts and cutaneous disease. Fibroblasts isolated from the skin of 
scleroderma patients exhibited elevated levels of constitutively active TAK1 protein (Shi-
wen et al., 2009). Decreased expression of collagen and other pro-fibrotic genes in the 
skin was observed in the fibroblast-specific TAK1 knock-out (TAK1-KO) mouse model, 
which also showed reduced skin thickness, delayed wound closure and decreased 
collagen deposition (Guo et al., 2012). TAK1-KO dermal fibroblasts exhibited reduced 
levels of proliferation (Guo et al., 2012).  Inhibition of TAK1 in human skin fibroblasts 
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using (5Z)-7-Oxozeaenol, a TAK1 selective inhibitor, also led to reduced expression of ~ 
66% of pro-fibrotic genes following in vitro treatment with TGFβ1 (Guo et at., 2012; 
Ninomiya-Tsuji et al., 2003). Thus, previous studies suggest that TAK1 plays an 
important role in maintaining dermal homeostasis as well as in mediating some of the 
pathways expected to play a role in fibrotic disease onset and progression.  
1.6.3 (5Z)-7-Oxozeaenol: a TAK1 selective inhibitor  
(5Z)-7-Oxozeaenol (also known as C 292, F 152, FR148083, L 783279, LL-
Z1640-2) is a natural resorcyclic lactone first isolated in 1978 from an unidentified 
fungus and later in 2003 from the f6024 fungal strain culture broth in a quest for 
identifying an inhibitor of TAK1 to combat  pro-inflammatory signaling (Ellestad et al., 
1978; Murray, 2009; Ninomiya-Tsuji et al., 2003). (5Z)-7-Oxozeaenol acts at the level of 
the ATP binding site of TAK1 to irreversibly inhibit TAK1 catalytic activity by forming 
a covalent bond with the C8’ of the cis-enone and Cys174 residue of TAK1 (Ninomiya-
Tsuji et al., 2003; Wu et al., 2013). A TAK1-specific IC50 of 8 nM and 65 nM was 
previously reported based on the in vitro and in vivo kinase assays respectively 
(Ninomiya-Tsuji et al., 2003). In comparison, the in vitro IC50 for MEKK1 was 268 nM 
and the activities of MEKK4 (another MAPKKK family representative) and ERK were 
not inhibited at 500 nM (5Z)-7-Oxozeaenol (Ninomiya-Tsuji et al., 2003). Downstream 
targets of TAK1 such as JNK and p38 were also not inhibited by (5Z)-7-Oxozeaenol 
(Ninomiya-Tsuji et al., 2003). 
1.7 TGFβ1 signaling: role of CCN2  
In dermal and gingival fibroblasts, TGFβ1 potently induces the expression of the 
pro-fibrotic marker and mediator CCN2 (connective tissue growth factor), a member of 
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the CCN family of matricellular proteins (named for the first three members: cyr61, ctgf 
and nov) (Black and Trackman 2008; Brigstock 2010; Leask 2008; Leask et al, 2009; 
Thompson et al., 2010). Matricellular proteins are known for their regulatory, as opposed 
to structural roles in modifying responses to growth factors and the microenvironment 
(Leask 2013a, 2013b.) Aside from CCN2, the CCN family in humans is comprised of 5 
other members classified together based on a predicted four-modular structure and 
presence of N-terminal secretory signal: cysteine-rich 61 (Cyr61/CCN1), nephroblastoma 
over-expressed (Nov/CCN3), and the Wnt-induced secreted proteins (WISP-1, CCN4), -2 
(WISP-2, CCN5) and 3 (WISP-3, CCN6) (Brigstock, 2003). CCN2 was identified over 
20 years ago by Bradham and others as a 38-kDa, cysteine-rich protein secreted in 
endothelial cell culture capable of inducing fibroblast chemotaxis and cell division 
(Bradham et al., 1991; Leask 2013a, 2013b).  The mature CCN2 protein is comprised of 
four modular domains: an insulin-like growth factor binding protein (IGFBP) domain 
(module I), a Von Willebrand factor domain (module II), a thrombospondin-homology 
domain (module III), cysteine knot heparin-binding domain (module IV) and possibly an 
un-cleaved signal peptide sequence. A “hinge region” between modules II and III allows 
for differential cleavage and fragmentation of the CCN2 protein which may have an 
effect on CCN2 function (Figure 1.5) (Bork 1993; Brigstock, 2003; Leask 2013a, 2013b; 
Perbal 2004). 
1.7.1 CCN2 mediates wound healing and fibrosis  
As observed with TGFβ1 expression, the levels of CCN2 increase rapidly 
following injury, and both the proliferative and remodeling phases of wound healing are  
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Figure 1.5. CCN2 protein structure (signal peptide and Modules I-IV) and signaling 
in fibroblasts. CCN2 binds integrins and heparan sulfate proteoglycan (HSPG) receptors 
on fibroblast surface. Binding of fibronectin and synergistic binding of TGFβ1 by CCN2 
transduces the signals from the ECM inside the fibroblast. (Adapted from: Figure 2. 
Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling 
modulators emerge from the bunker. J Cell Sci. 2006 Dec 1;119 (Pt 23):4803-10.  
Doi: 10.1242/jcs.03270; jcs.biologists.org) 
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regulated by CCN2-mediated response (Barrientos, et al., 2008). CCN2 expression is 
elevated in fibrotic conditions affecting all organs including atherosclerosis, scleroderma, 
keloids, hypertrophic scars, gingival hyperplasia, muscular dystrophy, Dupuytren’s 
disease, idiopathic pulmonary fibrosis as well as diabetic retinopathy and nephropathy 
(Barrientos et al., 2008; Holmes et al., 2001; Kantarci et al., 2006; Leask 2013a, 2013b; 
Leask et al., 2009; Ponticos et al., 2009; Sonnylal et al., 2010; Thompson et al., 2010; 
Uzel et al., 2001). Elevated levels of CCN2 expression also serve as indicators of the 
severity of systemic fibrosis and correlate well with the presence of myofibroblasts and 
elevated ECM production by fibroblasts (Leask and Abraham, 2006; Ponticos et al., 
2009). Loss of CCN2 expression in fibroblasts results in resistance to skin fibrosis, 
suggestive of the requirement of CCN2 for the development of skin fibrosis in vivo (Liu 
et al., 2011). CCN2 expression is induced by TGFβ1, yet it also behaves as a co-factor 
promoting TGFβ1-mediated ECM adhesion and fibrogenesis (Mori et al., 1998; Shi-wen 
et al., 2006; Wang et al., 2011) (Figure 1.5). CCN2 promotes fibroblast adhesion via 
association with HSPG and integrins, the specific identity of which tend to be cell type 
specific (Leask and Abraham, 2006). CCN2 potentiates other responses including: 
fibroblast growth, proliferation and chemotaxis, increase expression and deposition of 
collagen, fibronectin and other matrix proteins, up-regulation of integrin receptors, 
angiogenesis, endothelial migration, adhesion and proliferation (Barrientos et al., 2008; 
Holmes et al., 2001; Krieg et al., 2007; Leask 2008, 2013a, 2013b; Ponticos et al., 2009). 
The heparin binding domain also mediates the ability of CCN2 to bind low-density 
lipoprotein receptor-related protein 1 (LRP1) (Leask and Abraham, 2006; Segarini et al., 
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2001). Thus, understanding how CCN2 is regulated in fibroblasts is likely to yield 
valuable insights into the treatment of fibroproliferative disorders.   
1.8 Gingival hyperplasia   
In contrast to every other adult tissue, the oral cavity does not scar in response to 
injury (Egusa et al., 2010; Guo et al., 2011a, 2011b; Schor et al., 1996, Sciubba et al., 
1978). Unlike skin wounds, gingival wounds heal faster and without scarring, although 
the stages of the healing process and their sequence remain similar between the two tissue 
types (Egusa et al., 2010; Guo et al., 2011a, 2011b; Schor et al., 1996, Sciubba et al., 
1978; Wikesjo et al., 1992). One example of a fibrotic condition in the oral cavity is 
gingival hyperplasia, characterized by an excessive gingival overgrowth in susceptible 
patients as a side effect to antiepileptic medications, calcium channel blockers and 
immunosuppressant drugs or as a result of other factors including disease and genetic 
predisposition (Clocheret et al., 2003; Nakib and Ashrafi, 2011) (Figure 1.6).  In contrast 
to the typical, hyper-contractile response observed in fibrotic diseases, gingival 
hyperplasia is characterized by a hyper-proliferative response, likely due to the inherent 
tissue-specific differences in resident fibroblast cells (Guo et al., 2011a, 2011b). In vivo, 
fibrotic responses in the oral cavity are not generally characterized by the presence of 
myofibroblasts but instead are characterized by hyper-proliferation of fibroblast cells 
(Bitu et al., 2006; Damasceno et al., 2012; Sobral et al., 2010).  This feature could arise 
due to a reduced or altered sensitivity of gingival fibroblasts, relative to dermal 
fibroblasts to mechanical strain, TGFβ1 or the use of alternative TGFβ1 signaling  
pathways (Guo et al., 2011a,b). 
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Figure 1.6. Hereditary gingival overgrowth. Unlike skin, gingiva does not scar. In 
contrast to the hyper-contractile fibrotic disease presentation associated with 
myofibroblast differentiation, gingival hyperplasia is characterized by a fibroblast 
proliferation and relative lack of myofibroblasts in the oral cavity. Taken directly from: 
Fig. 1b. Orthodontic records after periodontal surgery. Clocheret K1, Dekeyser C, Carels 
C, Willems G., ‘Idiopathic gingival hyperplasia and orthodontic treatment: a case 
report.’, Journal of Orthodontics, 2003 Mar;30(1):13-9.  http://jorthod.maneyjournals.org/ 
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1.9 Human gingival fibroblasts vs dermal fibroblasts. What do we know? 
Studies analyzing transcriptional and functional differences among fibroblasts 
resident in various tissue niches are gaining importance with increasing evidence of inter- 
tissue fibroblast heterogeneity (Chang et al., 2002; Chipev et al., 2002; Ebisawa et al., 
2011; Guo et al., 2011a, 2011b; Yasuda et al., 2006). Although dermal and gingival 
fibroblasts appear to be morphologically identical in culture, differences at the level of 
gene expression have been previously reported (Ebisawa et al., 2011; Guo et al., 2011a, 
2011b). A study by Ebisawa and colleagues (2011) recently investigated differential gene 
expression in primary cultures (passages 4-5) of human gingival and dermal fibroblasts 
using DNA microarray, to gain a better insight into the existing functional differences of 
the two cell types (Ebisawa et al., 2011). From the 5284 analyzed genes, the expression 
of 5% (278) of genes was found to be significantly different; 114 genes were only 
expressed in dermal fibroblasts whereas 164 genes were only expression in gingival 
fibroblasts (Ebisawa et al., 2011). Differences in the extracellular matrix-related genes, 
oxidoreductase activity-related genes, cytokine activity-related genes and growth factor-
related genes were prominent between the two cell types (Ebisawa et al., 2011). A similar 
study using DNA microarray gene expression profiling identified close to 800 genes 
which were found to be enriched in the human dermal fibroblast cell line as compared to 
human gingival fibroblasts (Guo et al., 2011b). These included the pro-adhesive genes 
such as paxillin, integrins α2 and α4 and FAK (Guo, et al., 2011b).  In a different study, 
expression of integrins β3, a11, α2 and α5 exhibited 15-, 10-, 5- and 5- fold increased 
expression, respectively, in human dermal fibroblasts as compared to human gingival 
fibroblasts (Palaiologou et al., 2001). In contrast, expression of integrin subunit α3, α8 
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and β6 was found to be increased in gingival fibroblasts as compared to dermal 
fibroblasts by 50-, 15- and 5- fold, respectively (Palaiologou et al., 2001). Interestingly, 
no correlation was found between the expression pattern of heterodimeric integrin 
receptors and the fibroblast attachment profile to ECM (Palaiologou, et al., 2001). 
1.9.1 A comparison between gingival and dermal fibroblasts: differences in function  
The relative differences in wound healing and fibrotic responses between skin and 
gingiva may be further precipitated when fibroblasts are subjected to the wound 
healing/fibrogenic contexts and fibrogenic stimuli.  Three dimensional fibrin lattices have 
been used to culture fibroblasts to mimic cellular environment during the early phases of 
wound healing, including inflammation and formation of fibrin clot (Bell et al., 1983; 
Lorimier et al., 1996, 1998; Niewiaro et al., 1972). Gingival fibroblasts seeded onto a 
fibrin lattice resulted in a rapid retraction and lysis of the lattice and complete 
disappearance after one week, suggesting a higher degree of fibrinolytic activity in 
gingival fibroblast as compared to dermal fibroblasts (Lorimier et al., 1998). 
Interestingly, the expression of matrix metalloproteinases (MMP2, MMP9) and tissue 
inhibitors of metalloproteinases (TIMP2) was more rapid and robust by the gingival 
fibroblast, suggesting a greater capacity of matrix remodeling by the gingival as 
compared to dermal fibroblasts (Chaussain Miller et al., 2002) 
  Further, the shielding properties normally exhibited by the ECM matrix as a 
protective barrier from the external environment and mechanical forces may be lost as a 
result of injury and are thus thought to expose the fibroblasts to the forces of mechanical 
tension, followed by the differential adaptation of the two cell types to the new, “stress 
unshielded” environment, likely promoting fibroblast to myofibroblast differentiation  
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(Guo et al., 2011a; 2011b, Hinz and Gabbiani, 2003; Kessler et al., 2001).  Mechanical 
strain induced a number of pro-proliferative genes (CDC6, cdk6) as well as TGFβ1, ET-1 
(albeit at relatively low levels) and CCN2 gene expression in donor-derived human 
gingival fibroblasts whereas potent induction of collagen type I and αSMA did not occur 
(Guo et al., 2011a; 2011b). Further, the fibrotic gene cluster was not identified using 
microarray analysis of the gingival fibroblasts post 72 hour strain while genetic cluster 
involved in cellular proliferation (cdc6,cdk6) was induced in response to strain, 
consistent with the notion that gingiva possess a hyper-proliferative as opposed to hyper-
contractile fibrotic response (Guo et al., 2011a; 2011b).  
Similarly to strain, a six hour induction of human dermal fibroblasts with TGFβ1 
ligand (4ng/ml) potently increased the levels of CCN2, collagen I and α-SMA mRNAs, 
whereas only CCN2 expression was induced in human gingival fibroblasts in response to 
TGFβ1 albeit to a lesser extent than in dermal fibroblasts (Guo et al 2011a). The effect 
was attributed to the fact that gingival fibroblasts possess reduced ET-1 mRNA and 
protein as compared to human dermal fibroblasts; the difference in the  αSMA and 
collagen I induction between the two cell types was rescued upon co-incubation of 
gingival fibroblasts with both TGFβ and ET-1 (Guo, et al., 2011a). 
Further of interest is the observation that gingival wounds heal faster and with 
less scar formation as compared to skin wounds, although the stages of the healing 
process and their sequence remain similar between the two tissues (Egusa, et al., 2010; 
Guo et al., 2011a, 2011b; Schor, et al., 1996, Wikesjo, et al., 1992).  Therefore it is 
possible that TGFβ1 signals through different pathways in dermal vs gingival fibroblasts. 
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In this regard, the role of non-canonical TGFβ1 signaling in gingival fibroblast remains 
to be explored. (Guo et al, 2011a, 2011b).  
1.10 Rationale, Objectives and Hypothesis   
Canonical TGFβ1 signaling is involved in multiple intracellular signaling 
pathways and in a number of physiological and cellular processes (Datto et al., 1999; 
Grotendorst et al., 2004; Guo et al., 2012; Leask 2008; Mehra and Wrana 2002; Rahimi 
and Leof, 2007; Roberts et al., 1986; Yamashita et al., 2008). Thus, broad targeting of the 
TGFβ1- mediated pathways may lead to deleterious side effects; previous studies which 
tried to interfere with the downstream targets of the canonical TGFβ1 signaling yielded 
no promising results (Bonniaud et al., 2004a; Datto et al., 1999; Evans  et al., 2003; 
Grotendorst, et al., 2004; Hu  et al., 2003; Leask et at., 2008; Mehra and Wrana, 2002; 
Rahimi  and Leof, 2007;  Roberts et al., 1986; Wang, et al., 1997; Yamashita, et al., 
2008). Indeed, the use of CAT-192, a recombinant human anti-TGFβ1 antibody, led to 
adverse side-effects including death and no evidence of efficacy in the clinical trials of 
early-stage diffuse cutaneous systemic sclerosis treatment (Denton et al., 2007). Previous 
studies have identified the non-canonical, TAK1/JNK mediated signaling to play a role in 
physiological and pathological fibroblast function in the skin (Guo et al., 2012).  
Targeting the non-canonical pathways may thus represent a new and promising field in 
the development of novel therapeutics for the fibrotic disease treatment. 
The involvement of non-canonical, TAK1-mediated signaling in TGFβ1 driven, 
pro-fibrotic or hyper-proliferative responses in gingival fibroblasts has not been 
previously examined. Whether TAK1 mediates TGFβ1-driven fibro-proliferative 
responses in gingival fibroblasts is also unknown. In addition, the role of TAK1-mediated 
32 
 
CCN2 expression in gingival fibroblasts has not been previously investigated, although 
the known involvement of CCN2 signaling in fibrotic conditions including gingival 
hyperplasia render CCN2 as a promising target for future anti-fibrotic therapies (Black 
and Trackman, 2008; Blom et al., 2002).  Therefore, my overall objective was to use the 
TAK1 selective inhibitor (5Z)-7-Oxozeaenol to assess the role of TAK1 in human 
gingival fibroblast responses to TGFβ1. My hypothesis was that TAK1 mediates the 
ability of TGFβ1 to a) induce CCN2 expression and b) induce transcriptional responses in 
gingival fibroblasts. My thesis described data supporting the hypothesis that targeting the 
non-canonical TAK-mediated TGFβ1 signaling pathway may be useful to combat 
gingival hyperplasia in the future.  
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2. Materials and Methods 
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2.1 Human gingival fibroblast culture 
Gingival fibroblasts from one healthy human donor were used for this study and 
are described elsewhere (Thompson et al., 2010). Cells were grown as monolayers in 
high glucose DMEM growth media (Gibco) supplemented with 10% FBS (Gibco) and 
1% Antibiotic-Antimycotic mix (Gibco) at 37°C, 5% CO2 (SANYO Scientific laboratory 
incubator). At 40 -60% confluence, cultures were serum starved (low glucose DMEM 
growth media supplemented with 0.5% FBS and 1% Antibiotic-Antimycotic antibiotic 
mix) overnight and pre-treated with DMSO (vehicle control; Sigma-Aldrich) or 400 nM 
(5Z)-7-Oxozeaenol (Tocris) for 45 minutes followed by treatment with or without 
recombinant human TGFβ1 (4 ng/ml; 90 pM; R&D systems) for 6, 24, 48  and 72 hours 
as indicated (Guo et al., 2012). Cultures of passages 8 through 10 were utilized for this 
study.  
2.2 RNA extraction  
Cell monolayers were subjected to the total RNA extraction adapting the Trizol 
method as described previously (Ambion, Life-Technologies; Chomczynski and Sacchi, 
1987). Briefly, cell monolayers were lysed in TRIzol® (Ambion, Life Technologies) 
followed by the addition of 0.2 volumes chloroform (Sigma-Aldrich). The samples were 
centrifuged to allow for phase separation and ~70% of the supernatant was collected. 
Isopropanol (Sigma-Aldrich) was added in a 1:1 isopropanol to supernatant fraction 
volume ratio respectively and the samples were centrifuged to pellet the precipitated 
RNA. The latter was washed with 80% ethanol (GreenField Ethanol Inc), pelleted, air-
dried and re-dissolved in nuclease-free water (Thermo Fisher Scientific). The 
concentration and integrity of the extracted RNA sample was measured using the Nucleic 
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Acid, Nanodrop program (Thermo) and RNA quality was assessed using an Agilent 2100 
Bioanalyzer (Agilent Technologies Inc.) and RNA 6000 Nano kit (Caliper Life Sciences).  
The latter procedure was conducted at the London Regional Genomics Centre (David 
Carter, Robarts Research Institute, London, Ontario, Canada).  
2.3 RT-qPCR analysis 
Extracted RNA samples (50 ng) were reversed transcribed and amplified using 
TaqMan Human gene Expression assays (Applied Biosystems) in a 15-μL reaction 
containing qScript™ XLT One-Step RT-qPCR ToughMix (Quanta Biosciences), 
TaqMan Human gene specific target primers (Applied Biosystems) and FAM (6-
carboxyfluroscein labeled) gene specific TaqMan MGB probes (Assays on demand; 
Applied Biosystems) as per previously established protocols (Thompson et al., 2010).  
ViiA™ 7 Real-Time PCR System and ViiA™ 7 Software were used for detection and 
analysis of the amplified signal according to manufacturer’s instructions (Applied 
Biosystems). Relative gene expression was obtained for CCN2, IL11, PDGFA, EDN1, 
JUNB, IGFBP3 and SERPINE1 genes and standardized to the 18S expression as the 
internal control using the ΔΔCt method (Livak et al., 2001). Triplicate samples were 
examined and the experiments were repeated on three independent occasions with 
averages +/- SEM (N=3) calculated. Two-Way ANOVA and Tukey's Post Hoc analysis 
were used for statistical analysis (GraphPad Prism software). 
2.4 Genome-wide expression profiling 
All sample labeling and GeneChip processing was conducted by the London 
Regional Genomics Centre (David Carter, Robarts Research Institute, London, Ontario, 
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Canada) for two independent HGF treatment sets (DMSO, TGFβ1, (5Z)-7-Oxo as well as 
TGFβ1 + (5Z)-7-Oxo treated; Passages 8 and 9). Briefly, single stranded complementary 
DNA (sscDNA) was prepared from 200 ng of total RNA as per the Ambion WT 
Expression Kit for Affymetrix GeneChip Whole Transcript WT Expression Arrays and 
the Affymetrix GeneChip WT Terminal Labeling kit and Hybridization User Manual.  
Total RNA was first converted to cDNA, followed by in vitro transcription to make 
cRNA. Five and a half micrograms of single stranded cDNA was synthesized, end 
labeled and hybridized, for 16 hours at 45°C, to Human Gene 1.0 ST arrays (Affymetrix). 
All liquid handling steps were performed by a GeneChip Fluidics Station 450 and 
GeneChips were scanned with the GeneChip Scanner 3000 7G using Command Console 
v1.1 (Affymetrix). Probe level (.CEL file) data was generated using Affymetrix 
Command Console v1.1.  Probes were summarized to gene level data in Partek Genomics 
Suite v6.6 (Partek) using the RMA algorithm (Irizarry et al., 2003). Partek was used to 
determine gene level ANOVA p-values and fold changes.  Gene lists were created using 
a filter of 1.7 fold change and p-value of < 0.05.  Genes showing 1.7 fold induction and 
1.7 fold down regulation in the TGFβ1 + (5Z)-7-Oxozeaenol group as compared to the 
(5Z)-7-Oxozeaenol group alone were subtracted from the pool of TGFβ1 (1.7 fold) 
induced genes as compared to the DMSO control group. This resulting pool of (5Z)-7-
Oxozeaenol-dependent mRNAs with over 1.7 fold induction in response to TGFβ-1 
treatment was subject to Functional Annotation clustering (DAVID Functional 
Annotation Software). The 1.7 fold cut-off value was selected based on the previous 
analysis of TGFβ1 treated human dermal fibroblasts carried out in a separate study in our 
lab (Guo et al., 2012).   
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2.5 Western Blot analysis   
Cells were serum starved overnight, pre-treated with (5Z)-7-Oxozeaenol or 
DMSO followed by the treatment with or without recombinant human TGFβ1 as 
described previously. Cell monolayers were lysed 24 hours later in RIPA buffer (100 mM 
Tris HCl, pH 7.4; 150 mM NaCl; 1% NP40; 0.1% SDS; 5 mM EDTA) supplemented 
with  protease inhibitor mini complete tablet (Roche) and sonicated twice for 5 sec with 
concomitant 10 min incubation periods on ice. Samples were then centrifuged at 13,700 x 
g for 12 min at 4°C and the supernatant fraction collected. Total protein concentration of 
the lysates was established using the BCA assay microplate procedure (Pierce) based on 
the standard curve absorption values and the total protein content was equalized to 50 μg 
among all samples with Laemmli (63 mM Tris-Cl, pH 6.8; 10% glycerol; 5% β-
mercaptoethanol, 2% SDS, 0.01% bromophenol blue) and RIPA Lysis buffers as per 
manufacturer’s instructions (Pierce). The lysates were then incubated at 99°C for 5 min 
and loaded onto the 10% SDS gel  matrix  subjected to 130 V for ~2 hours in the 
presence of 1X Running buffer (5 mM Tris; 40 mM Glycine; 0.02% SDS) required for 
protein separation.  The 10% SDS gel was transferred onto nitrocellulose membrane 
using iBlot dry transfer kit and iBlot dry transfer machine (Invitrogen). The membranes 
were incubated for 1 hour in Blocking buffer solution (50 mM Tris, 150 mM NaCl; 
0.05% Tween®-20; 5% skim milk) followed by the addition of CCN2 (L-20) goat 
polyclonal primary antibody (Santa Cruz Biotechnology; sc-14939) in a 1:250 dilution 
and subsequent overnight incubation at 4°C. The following day, membranes were washed 
three times in TBST buffer (50 mM Tris, 150 mM NaCl; 0.05% Tween®-20) at room 
temperature for 10 min. Specific anti-goat secondary HRP conjugate polyclonal antibody 
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(Jackson Immunoresearch, Cat. 705-036-147) was added to the membrane in a 1:2000 
dilution in the blocking buffer and incubated for one hour at room temperature. Washing 
procedure was repeated and membranes imaged on X-ray film (Kodak) with the use of 
Chemiluminescent Substance (1:1 Lumino/Enhancer solution to Stable Peroxide Solution 
ratio; Thermo Scientific; Department of Dentistry, University of Western Ontario). 
Membranes were then washed in TBST and stripped with the Restore western blot 
stripping buffered (Thermo) for 20 min at room temperature, blocked and re-probed with 
β-actin mouse monoclonal primary antibody (Sigma, A1978-200UL; 1:8000 dilution) 
overnight at 4°C in TBST. Appropriate anti-mouse HRP conjugated antibody was chosen 
(Jackson Immunoresearch; 1:8000 dilution) to obtain β-actin signal intensity at the 1.5 
sec exposure time period. Densitometry measures for CCN2 band intensities for TGFβ1 
and TGFβ1 + (5Z)-7-Oxozeaenol treatment groups were obtained using ImageJ program 
(NIH) and standardized to the respective β-actin levels. Student’s t-test was used for 
statistical analysis (GraphPad Prism software). 
2.6 Indirect immunofluorescence procedure 
Cells cultured on glass coverslips (VWR) were fixed in 4% paraformaldehyde in 
PBS (10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl; pH 7.4), permeabilized with 
0.2% TritonX100 (Sigma-Aldrich) in PBS and blocked with 5% Donkey serum in PBST 
(10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl ,0.05% Tween® 20; pH 7.4) for 
30 min at room temperature followed by the addition of CCN2 (L-20) goat polyclonal 
antibody (Santa Cruz Biotechnology; sc-14939) in 1:100 dilution.  Following one hour 
incubation at room temperature, the samples were washed three times with PBS for 5 min 
and incubated with a DyLight 594 anti-goat IgG secondary antibody in a 1:1000 dilution 
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in 5% Donkey serum in PBST for 45 min at room temperature in the dark (Jackson 
ImmunoResearch Laboratories;  Cat. 705-516-147). The coverslips were washed with 
PBS (three times for 5 min) and mounted on the slides using VECTASHIELD
®
 
Mounting Media (Vector Laboratories). Images were taken with a Zeiss Axiophot 
microscope using Northern Eclipse software. Total fluorescence intensity was obtained 
using the Northern Eclipse software for each individual image and divided by the 
representative cell number obtained by using DAPI stain as a guide for the number of 
cells captured in each individual image. Relative fluorescence intensity ratio was further 
obtained using DMSO treatment group as a standard. Two-Way ANOVA and Tukey's 
Post Hoc analysis were used for statistical analysis (GraphPad Prism software). 
2.7 Proliferation Assay  
For the cell proliferation assay, cells were seeded in 96-well plates (Greiner Bio-
One) at 500 cells per well and cultured for one day in 10% FBS, high glucose DMEM 
media as described above. A “no-cell control” group was also incorporated involving 
only the addition of cell culture media. Cultures were then serum starved (0.5% FBS, low 
glucose DMEM) overnight and were pre-treated with DMSO (vehicle control) or 400 nM 
(5Z)-7-Oxozeaenol for 45 minutes followed by subsequent treatment with or without 
recombinant human TGFβ1 (4 ng/m; 90 pM) in quadruplicates. BrdU reagent (1X; Cell 
Signalling) was also added to all treatment groups at this time. The latter incorporates 
into the newly synthesised DNA. Cultures were incubated for zero, 24, 48 and 72 hours 
and subject to the BrdU proliferation assay using a kit as per manufacturer’s instructions 
(Cell Signalling). Briefly, cells were fixed and DNA denatured using a fixing/denaturing 
solution. Primary BrdU mouse mAb was added to bind the incorporated BrdU followed 
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by the addition of an anti-mouse IgG, HRP-linked antibody to bind the primary antibody. 
HRP substrate TMB was added to develop color and the plate incubated for 30 min 
followed by the addition of Stop solution. Proliferation was then determined from the 
absorbance values reading obtained at 450 nm (iMark™ microplate absorbance reader) 
and this corresponds to the quantity of BrdU incorporated into the cells. The raw data was 
processed for the detection and removal of outliers using the Interquartile Range 
calculation and was further noise adjusted by subtracting the average “no-cell control” 
reading from each individual well. Experiments were performed thrice. 
2.8 Statistical Analysis 
Student’s t-test, two-way ANOVA and Tukey's Post Hoc analysis were used for 
statistical analysis (GraphPad Prism software) where applicable. 
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3. Results 
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3.1  TAK1 mediates TGFβ1- induced gingival fibroblast CCN2 expression  
CCN2 is a matricellular protein of the CCN family implicated in fibro-
proliferative responses in fibroblasts (Chen and Lau, 2009; Leask and Abraham, 2006). 
CCN2 is up-regulated in response to TGFβ1 via canonical and non-canonical signaling 
pathways and acts to enhance TGFβ1-mediated fibroblast signaling responses 
(Grotendorst et al., 2006; Holmes et al., 2001; Mori et al., 1998; Thompson et al., 2010; 
Wang et al., 2011). Moreover, CCN2 is required for skin fibrosis in vivo (Liu et al., 
2011). In dermal fibroblasts, TGFβ1 induces CCN2 expression via TAK1 (Guo et al., 
2012). I thus investigated whether TAK1 mediates TGFβ1-induced CCN2 mRNA and 
protein expression using Real Time PCR analysis as well as Western blot and indirect 
immunofluorescence analysis, respectively. At the transcriptional level, TGFβ1 
significantly up-regulated CCN2 expression in gingival fibroblasts resulting in 7- fold 
increase in CCN2 mRNA levels similar to previously published results (Figure 3.1) 
(Thompson et al., 2010). Pre-treatment of gingival fibroblasts with (5Z)-7-Oxozeaenol, a 
TAK1 selective inhibitor (Ninomiya-Tsuji et al., 2003) 45 minutes prior to the addition of 
TGFβ1 resulted in a significant reduction of TGFβ1-induced CCN2 mRNA expression 
(Figure 3.1). Similar results were seen when protein expression was examined. CCN2 
protein levels were not readily detectable in unstimulated gingival fibroblasts using 
Western blot and indirect immunofluorescence analyses as anticipated from previously 
published data reporting low baseline CCN2 expression in gingival fibroblast cells 
(Thompson et al., 2010) (Figures 3.2 and 3.3). 
 
 
43 
 
 
 
 
         
 
 
 
 
 
 
 
Figure 3.1. TAK1 mediates TGFβ1 induced CCN2 gene expression. Human gingival 
fibroblasts were serum starved overnight and pre-treated with (5Z)-7-oxozeaenol (400 
nM) or DMSO for 45 min followed by treatment with TGFβ1 (4 ng/ml) ligand or left 
untreated. Total RNA was harvested six hours later and subjected to TaqMan RT-qPCR 
analysis using the indicated probe/primer set. 18S RNA was used as the internal control. 
Note: the relative gene expression between DMSO and (5Z)-7-oxozeaenol in the absence 
of TGFβ1 was not statistically significant. (N=3; averages+/-SEM are shown; *p<0.05, 
Two-Way ANOVA followed by Tukey's Post Hoc analysis).  
 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. TAK1 mediates TGFβ1 induced CCN2 protein expression: Western blot 
data. Human gingival fibroblasts were serum starved overnight and pre-treated with 
(5Z)-7-oxozeaenol (400 nM) or DMSO for 45 min followed by treatment with TGFβ1 
(4ng/ml) or left untreated for 24 hours. Proteins were harvested and subject to Western 
blot analysis with anti-CCN2 and anti-β-actin antibodies, as indicated. Experiments were 
performed on 4 separate occasions. (A) Representative blot is shown.  (B) Relative fold 
decrease in CCN2 expression in response to (5Z)-7-oxozeaenol pre-treatment was 
calculated using densitometry for TGFβ1 induced groups (N=4, averages +/ SEM are 
shown; * p<0.05; Student’s t-test) 
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Figure 3.3. TAK1 mediates TGFβ1-induced CCN2 protein expression: indirect 
immunofluorescence analysis. Human gingival fibroblasts were serum starved 
overnight and pre-treated with (5Z)-7-oxozeaenol (400 nM) or DMSO for 45 min 
followed by treatment for 24 hours with or without TGFβ1 (4 n/gml). Cells were fixed 
and stained with an anti-CCN2 antibody and DyLight 594 conjugated secondary 
antibody. Cells were counterstained with DAPI to detect nuclei. Experiments were 
conducted four times. (A) Representative micrographs are shown. White bar represents 
50 μm. (B) Total fluorescence intensity was obtained using the Northern Eclipse software 
for each individual image and divided by the representative cell number obtained by 
using DAPI stain as a guide for the number of cells captured in each individual image. 
Relative fluorescence intensity ratios were subsequently calculated using DMSO as a 
standard (N=4, averages +/ SEM are shown; * p<0.05, Two-Way ANOVA followed by 
Tukey's Post Hoc analysis). 
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Induction of cells with TGFβ1 increased CCN2 protein expression in both 
Western blot and immunofluorescence microscopy assays while the pre-treatment with 
(5Z)-7-Oxozeaenol resulted in a significant reduction of TGFβ1-induced CCN2 protein 
expression paralleling the results obtained by examining CCN2 mRNA expression 
(Figures 3.2 and 3.3). Indirect immunofluorescence analysis further revealed that 
induction of gingival fibroblasts cells with TGFβ1 resulted in the accumulation of CCN2 
in the cytoplasm, possibly Golgi apparatus as was previously reported for dermal 
fibroblasts (Chen et al., 2001); this accumulation was reduced in the presence of (5Z)-7-
Oxozeaenol (Figure 3.3). Given that CCN2 expression is a potent marker of TGFβ’s 
fibrogenic actions (Leask and Abraham, 2006) and that TGFβ1-induced CCN2 
expression in a TAK1-dependent manner, I thought that TAK1 may participate in 
mediating TGFβ1 fibrogenic responses in gingival fibroblasts.  
3.2 Inhibition of TAK1 blocks TGFβ1-induced mRNA expression in human 
gingival fibroblasts 
In order to further investigate a role of TAK1 in TGFβ1 signaling in gingival 
fibroblasts, cells were treated with or without TGFβ1 in the presence or absence of (5Z)-
7-Oxozeaenol inhibitor and subjected to gene expression profiling using GeneChip 
Human Gene 1.0 ST arrays. The use of gene expression profiling at the beginning of my 
study allowed me to (i) assess the extent of (5Z)-7- Oxozeaenol effect on the ability of 
TGFβ1 to induce genome-wide transcription and (ii) to identify functional categories of 
genes affected by TAK1 inhibition. Of the 28,869 genes provided on the Human 
GeneChip Gene 1.0 ST Arrays, 147 genes were up-regulated in response to TGFβ1 (1.7 
fold induction compared to DMSO control group), 139 of which were found to be 
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sensitive to (5Z)-7-Oxozeaenol inhibition (Figure 3.4). These results suggested that 
TAK1 mediates the majority (95%) of TGFβ1 signaling responses in gingival fibroblast 
cells (Ninomiya-Tsuji et al., 2003). Functional annotation of the 139 genes included 
clusters for cell cycle/proliferation as well as wound healing (including migratory) 
responses which became the focus of my subsequent analysis (Tables 3.1 and 3.2 
respectively).  
3.3  TAK1 mediates the induction of genes involved with proliferation  
Based on the expression profiling data, a proliferation cluster consisting of eight 
genes was identified (Table 3.1). Endothelin 1 and the Jun-B proto-oncogene were 
chosen as representative genes from this cluster based on their known involvement in 
scleroderma disease and pro-fibrotic programming in response to TGFβ respectively 
(Chung et al., 1996; Gervasi et al., 2012; Leask, 2008; Mauviel et al., 1993, Morelli et al, 
1995; Vancheeswaran et al., 1994; Yamane et al, 1992; 1996). Endothelin 1 (END1) is a 
secreted protein and a downstream target of TGFβ1 with increased levels observed in 
patients with fibrosis (Abraham et al., 1997; Kawaguchi et al., 1994; Leask, 2008; 
Miyauchi et al., 1992; Morelli et al, 1995; Shi-Wen et al., 2006; Vancheeswaran et al., 
1994; Yamane et al, 1992) while transcription factor Jun-B (JUNB) is induced by TGFβ1 
signaling in fibroblasts, mesenchymal and epithelial cells and is an important positive 
mediator of epithelial mesenchymal transition (Chung et al., 1996; Gervasi et al., 2012; 
Mauviel et al., 1993, 1996).  To confirm the microarray data and to establish whether the 
treatment of gingival fibroblasts with TAK1 inhibitor may hinder TGFβ1- induced 
proliferation at the transcriptional level, I cultured gingival fibroblasts in the presence or  
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Figure 3.4. (5Z)-7-oxozeaenol inhibits TGFβ1-induced mRNA expression in human 
gingival fibroblasts. Human gingival fibroblasts were serum starved overnight and pre-
treated with (5Z)-7-oxozeaenol (400 nM) or DMSO for 45 min followed by treatment 
with TGFβ1 (4 ng/ml) ligand or left untreated. Total RNA was harvested six hours later 
and subjected to gene expression profiling using GeneChip Human Gene 1.0 ST arrays 
(N=2). 147 genes were up-regulated in response to TGFβ1 (1.7 fold induction compared 
to DMSO control group) and 139 genes of the latter group were found to be sensitive to 
(5Z)-7-Oxozeaenol inhibition. 
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Table 3.1. Cluster analysis of mRNAs sensitive to TAK1 inhibition with over 1.7 fold 
induction in response to TGFβ-1 treatment.  (N=2; DAVID Functional Annotation 
Software). Cell cycle/Proliferation cluster 
  
 
 
 
 
 
Affymetrix 
ID 
GENBANK 
ACCESSION 
Gene name  Fold 
Increase 
8116921 AK291838 endothelin 1 EDN1 6.7818 
8024485 AF078077 growth arrest and DNA-damage-inducible, beta GADD45B 2.39958 
8139207 AK290584 inhibin, beta A INHBA 2.04306 
8026047 BC004250 jun B proto-oncogene JUNB 1.87672 
7922976 AK292167 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase) 
PTGS2 1.92186 
8147012 BC022265 
protein kinase (cAMP-dependent, catalytic) 
inhibitor alpha 
PKIA 2.41012 
8040473 AF498971 ras homolog gene family, member B 
RHOB 
  
1.88318 
8010061 AF200328 sphingosine kinase 1 SPHK1  1.72518  
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Table 3.2. Cluster analysis of mRNAs sensitive to TAK1 inhibition with over 1.7 fold 
induction in response to TGFβ-1 treatment.  (N=2; DAVID Functional Annotation 
Software).  
(A) Wound Healing cluster 
Affymetrix 
ID 
GENBANK 
ACCESSION 
Gene name  
 
Fold 
Increase 
7950933 AB041035 NADPH oxidase 4 NOX4 8.49418 
8160637  AK297541 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 1 
B4GALT1 2.12002 
8072678 BC001491 heme oxygenase (decycling) 1 HMOX1 2.05866 
8114572  BC033097 heparin-binding EGF-like growth factor HBEGF  4.0607 
8056184  AK290300 integrin, beta 6 ITGB6  2.41065 
8039484  AK290572 interleukin 11 IL11  1.84543 
8137670  AK292217 platelet-derived growth factor alpha polypeptide PDGFA  2.07886  
8135069  AK293248 
serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 1 
  
SERPINE1 2.17387 
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(B) Cell motion, migration and adhesion cluster 
Affymetrix 
ID 
GENBANK 
ACCESSION 
Gene name   Fold 
Increase 
8023220 AF010193 SMAD family member 7 SMAD7 2.841  
8160637  AK297541 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 1 
B4GALT1 2.12002  
8116921 AK291838 endothelin 1 EDN1 6.7818 
8072678  BC001491 heme oxygenase (decycling) 1 HMOX1  2.05866 
8114572 BC033097 heparin-binding EGF-like growth factor HBEGF 4.0607 
8139488 AK298143 insulin-like growth factor binding protein 3 IGFBP3  1.88748 
8137670  AK292217 platelet-derived growth factor alpha polypeptide PDGFA  2.07886 
8010061  AF200328 sphingosine kinase 1 SPHK1  1.72518 
8148304  AF205437 tribbles homolog 1 (Drosophila) TRIB1  2.96456  
7962579  AY454159 adhesion molecule with Ig-like domain 2 AMIGO2  3.45511 
8022674 BC036470 cadherin 2, type 1, N-cadherin (neuronal) CDH2  2.04821  
8035517  AK074508 cartilage oligomeric matrix protein COMP  3.02008  
8121685  AJ420528 discoidin, CUB and LCCL domain containing 1 DCBLD1  1.85226 
8056184  AK290300 integrin, beta 6 ITGB6  2.41065 
8102232  AF198532 lymphoid enhancer-binding factor 1 LEF1  1.90975  
8123936  AK292682 
neural precursor cell expressed, developmentally 
down-regulated  
NEDD9  2.93624 
8047738  AL833606 neuropilin 2 NRP2  1.73487  
8040473  AF498971 ras homolog gene family, member B RHOB 1.88318  
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absence of (5Z)-7-Oxozeaenol and with and without TGFβ1 treatment. Six hours later 
RNAs were extracted and subjected to RT-qPCR analysis. Confirming the gene array 
data, both EDN1 and JUNB mRNA were found to be significantly induced by TGFβ1 
ligand and application of the TAK1 selective inhibitor (5Z)-7-Oxozeaenol inhibited this 
response (Figure 3.5). Indeed, in the presence of TGFβ1 and (5Z)-7-Oxozeaenol, EDN1 
and JUNB mRNA expression were reduced to basal levels seen in DMSO treated 
fibroblasts. Addition of (5Z)-7-Oxozeaenol did not have a significant effect on EDN1 and 
JUNB  mRNA expression (Figure 3.5).  
3.4 TAK1 inhibition blocks TGFβ1-induced proliferation in gingival 
fibroblasts.  
To further elucidate gingival fibroblast proliferation at the functional level, I 
cultured gingival fibroblasts under the four treatment conditions described previously in 
the presence of BrdU, a synthetic thymidine analogue which is incorporated into the 
newly-synthesized DNA (Figure 3.6). Presence of incorporated BrdU was assessed 
quantitatively by absorbance readings at zero, 24, 48 and 72 hours. Addition of TGFβ1 
significantly increased human gingival fibroblast proliferation at 48 and 72 hours as 
compared to DMSO treated cells. Addition of (5Z)-7-Oxozeaenol resulted in a significant 
reduction in cell proliferation responses measured at 72 hours to the levels below the 
DMSO control group in the presence of added TGFβ1 (Figure 3.6). Consistent with the 
gene cluster analysis, TAK1 inhibition blocked the ability of TGFβ1 to induce 
proliferation in human gingival fibroblasts.  
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Figure 3.5. Inhibition of TAK1 reduces TGFβ1-induced Endothelin 1 and Jun B 
mRNA expression. Human gingival fibroblasts were serum starved overnight and pre-
treated with (5Z)-7-oxozeaenol (400 nM) or DMSO for 45 min followed by treatment 
with TGFβ1 (4 ng/ml) ligand or left untreated. Total RNA was harvested six hours later 
and subjected to TaqMan RT-qPCR analysis using the indicated probe/primer sets. 18S 
RNA was used as the internal control. Note: the relative gene expression between DMSO 
and (5Z)-7-oxozeaenol in the absence of TGFβ1 was not statistically significant. (N=3; 
averages+/-SEM are shown. * p<0.05; Two-Way ANOVA followed by Tukey's Post Hoc 
analysis). 
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Figure 3.6. TAK1 mediates TGFβ1 induced gingival fibroblast proliferation. Human 
gingival fibroblasts were serum starved overnight and pre-treated with (5Z)-7-oxozeaenol 
((5Z)-7-oxo; 400 nM) or DMSO for 45 min followed by treatment with TGFβ1 (4 ng/ml) 
ligand or left untreated. Cultures were grown in the presence of BrdU for up to 72 hours 
as described in the methods. One of three representative experiments is shown; (N=4; 
averages+/-SEM are shown * p<0.05 for: DMSO vs TGFβ1; (5Z)-7-oxo vs TGFβ1, 
TGFβ1 vs (5Z)-7-oxo+TGFβ1; ** p<0.05 for: DMSO vs TGFβ1; (5Z)-7-oxo vs TGFβ1, 
TGFβ1 vs (5Z)-7-oxo+TGFβ1. Two-Way ANOVA followed by Tukey's Post Hoc 
analysis. 
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3.5  TAK1 mediates TGFβ1- induced expression of wound healing cluster 
mRNAs in gingival fibroblasts 
Based on the expression profiling data, a wound healing cluster of eight genes as 
well as a migration cluster consisting of eighteen genes were also identified (Table 3.2). I 
decided to use RT-qPCR analysis to validate these observations and to further investigate 
the role of TAK1 inhibition in the fibrotic component of the TGFβ1-dependent 
fibroproliferative responses of fibroblast cells. Based on their known involvement with 
fibrogenic responses, insulin-like growth factor binding protein 3 (IGFBP3) was chosen 
from the migration/adhesion cluster group and platelet-derived growth factor-α-
polypeptide (PDGFA), Interleukin-11 and SERPINE-1 genes were chosen from the 
wound healing cluster group for the subsequent RT-qPCR analysis (Figure 3.7). IL11 
was previously implicated as an anti-apoptotic mediator in lung fibroblasts derived from 
Idiopathic Pulmonary Fibrosis patients and increased murine pulmonary myofibroblast 
counts upon IL11 overexpression were also reported (Moodley et al., 2003). PDGFA is a 
secreted protein and mitogen belonging to the Platelet-derived growth factor family 
found to be overexpressed in a number of fibrotic conditions including pulmonary 
fibrosis and scleroderma at the level of fibroblasts/myofibroblasts (Trojanowska 2008). 
IGFBP3 is another secreted protein associated with increased ECM production and ECM 
binding in a TGFβ-dependent manner. Increased expression of IGFBP3 was observed in 
dermal fibroblasts from scleroderma patients and lung fibroblasts from idiopathic 
pulmonary fibrosis patients (Pilewski et al., 2005). Finally, elevated levels of SERPINE1, 
a pro-fibrogenic factor, were observed in the dermal fibroblasts isolated from the lesions 
of scleroderma patients (Dong et al., 2002; Ghosh          
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Figure 3.7. Inhibition of TAK1 reduces the expression of TGFβ1 induced wound 
healing genes. Human gingival fibroblasts were serum starved overnight and pre-treated 
with (5Z)-7-oxozeaenol (400 nM) or DMSO for 45 min followed by treatment with 
TGFβ1 (4 ng/ml) ligand or left untreated. Total RNA was harvested six hours later and 
subjected to TaqMan RT-qPCR analysis using the indicated probe/primer sets. 18S RNA 
was used as the internal control. Note: the relative gene expression between DMSO and 
(5Z)-7-oxozeaenol in the absence of TGFβ1 was not statistically significant. (N=3; 
averages+/-SEM are shown. * p <0.05, Two-Way ANOVA followed by Tukey's Post 
Hoc analysis). 
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and Vaughan, 2012).  RT-qPCR analysis confirmed the gene array data, showing that 
IL11, PDGFA, IGFBP3 and SERPINE1 mRNAs were significantly induced by TGFβ1 in 
a fashion that was sensitive to TAK1 inhibition (Figure 3.7). Baseline expression of all 
of the chosen genes was not significantly affected with the addition of (5Z)-7-
Oxozeaenol.  
Collectively, these data suggest that TAK1 mediates TGFβ1 responses in gingival 
fibroblasts including proliferation, wound healing as well as CCN2 expression.  
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4. Discussion  
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4.1 Summary of results  
Although previous studies have shown that the non-canonical, TAK1-mediated 
signaling pathway plays a role in dermal fibroblasts and in physiological wound healing 
in the skin, the involvement of non-canonical TAK1 signaling in TGFβ1 driven, pro-
fibrotic or hyper-proliferative responses in gingival fibroblasts has not been previously 
examined (Guo et al., 2012). I thus thought that, as in dermal fibroblasts, TAK1 may 
mediate wound healing and proliferative responses in gingival fibroblasts in response to 
TGFβ1. Throughout my studies I have used a TAK1 selective inhibitor  (5Z)-7-
Oxozeanol to test this hypothesis in the context of TGFβ1 signaling in gingival 
fibroblasts using concentrations and treatment conditions previously established for 
fibroblasts in culture (Guo et al., 2012; Renzoni et al., 2004 ). As an initial screen, I asked 
if (5Z)-7-Oxozeanol could block TGFβ1- induced CCN2 expression, given that CCN2 is 
a known marker and mediator of fibrosis (Brigstock 2010; Chen and Lau, 2009; Leask, 
2008, 2009; 2011; 2013a, 2013b, Thompson et al., 2010). Indeed, (5Z)-7-Oxozeanol 
significantly reduced TGFβ1-induced CCN2 expression at both transcriptional and 
translational levels as evidenced by the RT-qPCR and indirect immunofluorescence 
microscopy/Western blot respectively (Figures 3.1, 3.2 and 3.3). Genome wide 
expression profiling allowed me to further identify functional clusters of genes grouped 
based on their involvement in a given functional outcome. I have identified a number of 
TGFβ1-induced genes sensitive to TAK1 inhibition from the proliferative and wound 
healing (including migratory) clusters (Tables 3.1 and 3.2, respectively). Moreover, the 
majority of the genes induced with TGFβ1 were in fact sensitive to TAK1 inhibition, 
suggesting that the non-canonical TAK1 pathway is of critical importance in the gingival 
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fibroblasts in response to TGFβ1. I have also confirmed this pattern of regulation for a 
number of representative genes from each functional cluster at the transcriptional level 
using RT-qPCR (Figures 3.5 and 3.7). Of interest also was the observation that unlike 
skin wounds, gingival wounds heal faster and without scarring, possibly due to the fact 
that unlike fibroblasts from the dermis layer of the skin, gingival fibroblasts are also less 
able to differentiate into α-SMA-expressing myofibroblasts in vitro and in vivo: gingival 
hyperplasia overgrowths are not populated by myofibroblast and with respect to fibrotic 
conditions, such as gingival hyperplasia, a hyperproliferative phenotype is observed 
(Egusa et al., 2010; Guo et al., 2011a, 2011b; Schor et al., 1996, Wikesjo et al., 1992).  I 
thus became interested whether the TGFβ1-induced proliferation in gingival fibroblasts 
may be mediated by TAK1 and whether TAK1 inhibition using an exogenously 
administered inhibitor could in theory be applied to alleviate the fibro-proliferative 
responses in gingival hyperplasia in the future. Indeed, increased proliferative responses 
of gingival fibroblasts upon TGFβ1 treatment were reduced to baseline levels with the 
application of TAK1 selective inhibitor (5Z)-7-Oxozeanol (Figure 3.6). Collectively, my 
work suggests that TAK1 mediates proliferation and wound healing responses to TGFβ1 
in gingival fibroblasts. The results are also consistent with my long-term hypothesis that 
TAK1 inhibition might be used to treat gingival hyperplasia and that further investigation 
of TAK1-mediated TGFβ1 signaling in gingival fibroblast cells may lead to a better 
understanding of a) the basis of gingival scarless repair and b) the role of the non-
canonical, TAK1- mediated TGFβ1 signaling as it pertains to the hyper-proliferative 
response associated with this fibroblast cell type. 
62 
 
4.2 Research significance    
My results are consistent with the overall hypothesis that TAK1 inhibitors such as 
(5Z)-7-Oxozeanol may be considered in the future for gingival hyperplasia treatment.  
Unlike other areas of the body which scar in response to injury,  gingival wounds heal 
faster and without scarring, although the stages of the healing process and their sequence 
remain similar between the two tissue types (Egusa et al., 2010; Guo et al., 2011a, 2011b; 
Schor et al., 1996, Wikesjo et al., 1992). One of the possible explanations for this 
differential phenotype is that fibrotic responses in the gingiva are hyper-proliferative as 
opposed to hypercontractile (Bitu et al., 2006; Damasceno et al., 2012; Sobral et al., 
2010). The basis of this differential phenotype could be that gingival fibroblasts differ 
from dermal fibroblasts in their response to endogenous and/or exogenous stimuli, 
resulting in gingival overgrowth and hyperplasia (Guo et al., 2011a, 2011b). Gingival 
hyperplasia commonly arises as a side-effect to a number of drugs including antiepileptic 
medications, immunosuppressant drugs and as well as calcium channel blockers 
(Clocheret et al., 2003; Nakib and Ashrafi, 2011). Prevalence of gingival hyperplasia 
associated with Diltiazem (calcium channel blocker) reaches 20% while Cyclosporine 
(immunosuppressant) or Phenytoin (antiepileptic treatment) are associated with 30% and 
40-50% prevalence rate respectively (Boltchi et al., 1999; Casetta et al., 1997; Ciancio et 
al., 1991; Dahlof et al., 1993; Fu et al., 1998; Myers and Newton, 1991; Steinberg 1981). 
As of 1995, over 20 prescription medications were associated with gingival enlargement 
in the United States (Rees et al., 1995). Withdrawal from drug therapy or substitution for 
a different drug serves as the most effective treatment for gingival hyperplasia however 
gingivectomy (surgical debridement) may be necessary in cases where 
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withdrawal/substitution are not possible or in all other cases of gingival hyperplasia 
(including inflammation, idiopathic gingival hyperplasia, gingivitis, genetic 
predisposition) (Khocht et al., 1997; Marshall et al., 1999; Somacarrera et al., 1997).   
TGFβ1, a member of TGFβ superfamily, promotes wound healing and fibrotic 
responses both in vitro and in vivo (Leask 2008). Fibroblasts are the cells present in the 
connective tissue that mediate tissue repair and fibrosis. Fibroblast activation in response 
to TGFβ1 involves both canonical Smad-dependent and non-canonical Smad-independent 
pathways (Leask 2006, 2008; Leask and Abraham, 2004; Massague 1998; Rahimi and 
Leof, 2007). At the level of transcriptome, close to 95% of genes were up-regulated in 
response to TGFβ1 in gingival fibroblasts were found to be sensitive to TAK1 inhibition.  
In contrast, only 67% of genes were not induced by TGFβ1 in the presence of (5Z)-7-
Oxozeaenol in dermal fibroblasts in a study using comparable fold cut-off value (1.7 
fold) and treatment conditions (400 nM (5Z)-7-Oxozeaenol; 4 ng/ml TGFβ1) (Guo et at., 
2012). Thus, compared to dermal fibroblasts, the vast majority of TGFβ1 signaling 
responses in gingival fibroblasts are mediated via the non-canonical TAK1 pathways. In 
dermal fibroblasts, wound healing and ECM gene clusters were identified for the TGFβ1 
induced genes sensitive to TAK1 inhibition (Guo et at., 2012). Similarly, the wound 
healing cluster under TAK1 regulation was also identified in gingival fibroblasts in the 
current study, as well as a cluster cell proliferation.  
CCN2, a member of the CCN family of matricellular proteins is both a marker 
and a mediator of fibrosis (Blom et al., 2002; Brigstock 2010; Chen and Lau, 2009; 
Leask, 2008, 2009; 2011; 2013a, 2013b, Thompson et al., 2010). CCN2 expression is 
also known to be induced by TGFβ1 in gingival and dermal fibroblasts and expression of 
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this protein correlates well with tissue fibrosis and fibrotic cells (Brigstock, 2010; Chen 
and Lau, 2009; Guo et al., 2011a, 2011b; Leask, 2008, 2011). In gingival and dermal 
fibroblasts, TGFβ1-induced CCN2 expression is known to involve canonical signaling 
pathways (Guo et al., 2011a; Holmes et al., 2001; Thompson et al., 2010). Previously, 
mRNA and protein expression of CCN2 in dermal fibroblasts were found to be reduced 
with the (5Z)-7-Oxozeanol, a selective inhibitor of the non-canonical TAK1 signaling in 
response to TGFβ1 treatment.  Here I show for the first time that (5Z)-7-Oxozeanol 
suppresses the ability of TGFβ1 to induce CCN2 mRNA as well as protein expression in 
gingival fibroblasts. CCN2 expression in response to TGFβ1 may thus be subject (at least 
in part) to the non-canonical regulation in both dermal and gingival fibroblasts.  
Previous studies demonstrated that CCN2 showed increased expression in fibrotic 
tissues where it promoted fibrosis by activating adhesive signaling (Brigstock, 2010; 
Chen and Lau, 2009; Leask, 2008, 2011). Adhesive properties of gingival and dermal 
fibroblasts were also previously assessed using dermal or gingival fibroblast monolayers 
cultured on collagen type I and III, fibronectin and vitronectin substrates. Dermal 
fibroblasts were more spread out and displayed increased number of focal adhesions and 
actin stress fibers as compared to gingival fibroblasts up to 24 hours post adhesion on 
either collagen type I or fibronectin substrates (Guo et al., 2011a; 2011b). Adhesion via 
FAK is essential for TGFβ1-induced human fetal lung myofibroblast differentiation 
(Thannickal et al., 2003). FAK is further involved in driving myofibroblast differentiation 
via the non-canonical TGFβ signaling pathway involving FAK-mediated JNK activation 
via MEKK1 (Shi-wen et al., 2009).  FAK forms a complex with integrin receptors is and 
activated upon integrin mediated fibroblast attachment to the substrate (Lagares et al., 
65 
 
2012; Michael et al., 2009; Shi-wen at al., 2012).  Addition of FAK inhibitor or deletion 
of FAK in fibroblasts decreased the expression of fibrogenic genes and blocked fibrosis 
in vivo (Lagares et al., 2012; Shi-wen et al., 2012). Inhibitors of FAK and integrins (β1) 
have been proposed as potential therapeutic agents in alleviating the symptoms of 
scleroderma disease (Shi-wen et al., 2012). Interestingly, the endogenous levels of FAK 
protein are also reduced in gingival fibroblasts as compared to dermal fibroblasts (Guo et 
al., 2011a, 2011b) perhaps accounting (at least in part) for the impaired myofibroblast 
differentiation potential and impaired adhesion kinetics of gingival fibroblasts as 
compared to dermal fibroblasts. Induction of TAK1 upon TGFβ stimulation was further 
reduced upon pre-treatment of wild type mouse embryonic fibroblasts with the FAK/Src 
inhibitor PP2, or with the use of FAK -/- fibroblasts, suggestive of FAK-dependent 
induction of TAK1 in TGFβ signaling (Shi-wen et al., 2009).  As TAK1-dependent 
TGFβ1 signaling operates in both gingival and dermal fibroblasts, additional signaling 
pathways must be responsible for the fibro-contractile phenotype observed in fibrotic 
tissue in other parts of the body. Indeed, Chen and others report TGFβ1-induced 
contraction of dermal fibroblasts to be syndecan 4 and MEK/ERK dependent; notably, 
ERK was required for assembly of α-SMA stress fibers and hence ECM contraction 
(Chen et al., 2005). Alternatively, TGFβ1 signaling may be subject to epigenetic 
regulation in gingival versus dermal fibroblasts, accounting for scarless repair; indeed, 
recent results from our laboratory suggest that expression of microRNA MIR218 is 
altered between gingival and dermal fibroblasts (Guo et al., 2014).  
Endothelin-1 was also chosen as a representative gene from the proliferative 
cluster showing decreased TGFβ1-mediated mRNA expression levels with (5Z)-7-
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Oxozeaenol pre-treatment. ET-1 belongs to a family of peptides originally recognized for 
their role as vasoconstrictors and section from vascular endothelial cells (Horstmeyer et 
al., 2005; Kawaguchi et al., 1994; Shi-wen et al., 2006).  Levels of ET-1 expression were 
found to be increased in a number of fibrotic disease conditions including drug induced 
gingival overgrowth and gingival fibrosis (Abraham et al., 1997; Kawaguchi et al., 1994; 
Leask, 2008; Miyauchi et al., 1992; Morelli et al, 1995; Shi-Wen et al., 2006; Subramani  
et al., 2013; Tamilselvan et al., 2007; Vancheeswaran et al., 1994; Yamane et al, 1992).  
ET-1 is a 21-amino acid ligand produced by fibroblasts and other cell types (epithelial 
and endothelial cells, cardiomyocytes, smooth muscle and immune cells) in a form of an 
inactive prepro-ET1 which is further processed by endopeptidase and endothelin-
converting enzyme (ECE) into a proET-1 and active ET-1 respectively (Horstmeyer et 
al., 2005; Kawaguchi et al., 1994; Leask 2008; Shi-wen et al., 2001, 2006; Tamilselvan et 
al., 2007). ET-1 acts synergistically with TGFβ to promote differentiation of fibroblasts 
into myofibroblast and is also induced by, and mediates downstream signaling in 
response to TGFβ (Galie et al., 2004; Horstmeyer et al., 2005; Krieg et al., 2007; Rahimi 
and Leof, 2007; Rodriguez et al., 2003; Shephard et al., 2004). Stimulation of dermal 
fibroblasts with ET-1 alone did not lead to sufficient up-regulation of α-SMA, a marker 
of myofibroblast differentiation while a synergistic increase in α-SMA expression  was 
observed upon co-stimulation with ET-1 and TGFβ1(Shephard et al., 2004). Similarly, 
inhibition of endogenous TGFβ1 activity using a neutralizing antibody as well as co-
inhibition of ET-1 activity were required to completely prevent α-SMA expression in 
keratinocyte-fibroblast co-cultures (Shephard et al., 2004). Interestingly, gingival 
fibroblasts possess reduced EDN1 mRNA and ET-1 protein expression as compared to 
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human dermal fibroblasts. Subjecting gingival fibroblasts to mechanical strain or a six 
hour induction with TGFβ1 (4ng/ml) did not result in up-regulation of collagen type I or 
αSMA, as was the case with dermal fibroblasts under the same culture conditions (Guo et 
al., 2011a,b). These differences in the αSMA and collagen I induction between the two 
cell types were rescued upon co-incubation of gingival fibroblasts with both TGFβ and 
ET-1. That myofibroblast differentiation is relatively absent in fibrotic conditions such as 
gingival hyperplasia may thus be partially explained by the reduced gingival fibroblast 
responsiveness (αSMA and collagen expression) to mechanical strain and TGFβ1 
induction as a result of a reduced production of ET-1, as compared to dermal fibroblast 
cells (Bitu et al., 2006; Damasceno et al., 2012; Guo et al., 2011a,b; Sobral et al., 2010).  
Aside from the active role in ECM remodeling and myofibroblast differentiation, 
ET-1 exhibits mitogenic properties as well as production of PDGF and TNF-α 
inflammatory cytokines and TGFβ1 (Chamnez et al., 1996; Gandhi et al., 2000; 
Horstmeyer et al., 2005; Nakamura et al., 1995; Shi-wen et al., 2001). Expression of ET-
1 upon TGFβ1 treatment was found to be subject to canonical as well as non-canonical 
JNK regulation in human dermal and mouse embryonic fibroblasts (Lagares et al., 2010). 
Furthermore, ET-1 expression in response to TGFβ1 is Smad-independent in the 
pulmonary fibroblast cells subject to comparable TGFβ1 induction (4 ng/ml) and is 
instead mediated via the JNK/c-Jun/activator protein-1(AP-1) (Krieg at al., 2007; Shi-
Wen et al., 2006).  As these data suggest that TAK1 regulates JNK activation, the non-
canonical TAK1 signaling pathways may mediate TGFβ1 induced ET-1 expression in 
lung fibroblasts (Rahimi and Leof, 2007).  Based on the results I present here, TGFβ1-
induced EDN1 mRNA expression was blocked by TAK1 selective inhibitor, suggesting 
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that ET-1 may be regulated in a similar fashion in both pulmonary and gingival 
fibroblasts. Inhibition of TAK1 in gingival fibroblasts may lead to inhibition of the 
JNK/c-Jun/activator protein-1(AP-1) signaling similar to what was reported in pulmonary 
fibroblasts (Rahimi and Leof, 2007). In fibroblasts, TGFβ1 and ET-1 synergize to 
promote myofibroblast differentiation (Shephard et al., 2004). It also is interesting to note 
that basal ET-1 expression in human gingival fibroblasts is lower than that in dermal 
fibroblasts and this lower level of expression may explain why TGFβ1 is relatively 
unable to induce myofibroblast differentiation in gingival fibroblasts (Guo et al., 2011a, 
2001b) 
4.3 Limitations and future research 
The results suggest that TAK1 pathway operates in gingival fibroblasts and 
mediates essentially all responses to TGFβ1, including proliferation and CCN2 induction. 
These results must nevertheless be interpreted with caution since the mRNA expression 
levels of individual genes should not be examined in the context of gene expression 
profiling alone, but needs independent verification through other procedures. In this 
thesis, the results obtained using gene array profiling were verified using real time PCR 
analysis and functional assay.  
A confounding factor may be equally present among the various treatment 
conditions in this study, as I cultured gingival fibroblasts on rigid, stiff plastic tissue 
culture plates. Progressive increases in the matrix stiffness during normal wound healing 
is thought to correlate with fibroblast-myofibroblast differentiation as mechanical tension 
encourages the formation of focal adhesion and stress fibers (Hinz, 2010; Hinz et al., 
2001; Balestrini et al., 2012). In theory, this finding is not surprising given the current 
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knowledge of the role of ECM in sheltering the residing fibroblasts from the outside 
mechanical forces as well as the observation of a loss of fibroblast phenotype and 
emergence of myofibroblasts when the “stress-shielding” capacity of ECM is lost  upon 
injury (Guo et al., 2011a, 2011b; Hinz and Gabbiani 2003).  In addition, the later stages 
of wound healing response are characterized by the ECM remodeling and increases in the 
ECM stiffness. Compliant, two-dimensional matrices were therefore developed in the 
past with polyacrylamide, polyvinyl alcohol or silicone based elastomers (Hinz, 2010).  
Although soft, two dimensional matrices are thought to serve as better models of 
true tissue compliance, the use of such compliant two dimensional matrices is also not 
without limitations.  First, the true tissue compliance is complex and not homogenous 
(Hinz, 2010). Second, matrices of polyacrylamide or silicone cannot be remodeled by the 
attached fibroblast cells as these synthetic substances are not biologically degradable 
(Hinz, 2010). This creates several important limitations in terms of experimental design. 
Increases in the deposition of collagen and other factors by the cultured cells may 
overcome the effects of the underlying soft matrix, effectively increasing its stiffness 
(Hinz 2010). The degree of culture confluence may further overturn the effect of soft 
matrix when the increased formation of cell-cell contacts leads to increased mechanical 
tension exerted on the cell culture by cells (Hinz 2010).  In contrast, the three- 
dimensional matrices of collagen or fibronectin completely surround cells in culture and 
may better represent the microenvironment encountered by the fibroblast in the lamina 
propria layer (Grinnell, 2003). Three dimensional culture matrices have been also 
previously employed to better recreate the physiological conditions experienced by the 
fibroblasts in the dermis or lamina propria layers, including the presence of cell-cell and 
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cell-matrix adhesions, regulation of cellular proliferation and growth as well as in vivo 
wound healing and remodeling responses (Chaussain Miller et al., 2002). 
Consequently, although it might have been interesting to compare the responses 
of gingival fibroblast cultured on more compliant and elastic substrates or in using three 
dimensional matrices, that TGFβ1 still potently induced gene expression and proliferation 
of cells cultured on plastic suggests that alteration in fibroblast phenotype due to 
culturing cells on plastic is not sufficient to cause a complete differentiation of fibroblasts 
to myofibroblast. CCN2 is both a marker and a mediator of fibrosis, and expression of 
this protein correlates well with tissue fibrosis and fibrotic cells (Brigstock, 2010; Chen 
and Lau, 2009; (Guo et al., 2011a, 2011b; Leask, 2008, 2011). I did not detect basal 
CCN2 protein expression (DMSO treatment group) using two separate methods of 
analysis: western blot and immunofluorescence microscopy and should gingival 
fibroblast cells undergo this process of differentiation in response to the stiff, plastic 
substrate, high basal expression of CCN2 in cultured gingival fibroblasts would have 
been apparent. Further, induction of gingival fibroblast monolayers with TGFβ1 lead to 
robust responses not only in CCN2 expression (mRNA and protein) but also in the 
expression of wound healing and proliferative genes as well as measures of gingival 
fibroblast proliferation using a functional assay. Had gingival fibroblast cells undergone 
the process of differentiation in response to the stiff substrate, additional induction with 
TGFβ1 would likely have not caused significant effects. That fibrotic conditions such as 
gingival hyperplasia are characterized by increased proliferation of fibroblast cells, as 
opposed to differentiation into myofibroblasts, further supports the notion that gingival 
fibroblasts respond differently to the fibrogenic stimuli such as TGFβ1 induction or 
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“stress-unshielded” environment provided by the rigid plastic culture vessel (Bitu et al., 
2006; Damasceno et al., 2012; Sobral et al., 2010). Three-dimensional collagen or 
fibronectin lattices  nevertheless  may be utilized in the future studies of gingival 
fibroblast ECM remodeling in the presence and absence of (5Z)-7-oxozeaenol. 
The use of an animal model to study the role of TAK1 in gingival fibroblasts 
should be considered for the future. Full body MAP3K7-KO (deletion of TAK1) mice die 
in utero during early embryogenesis (E10) likely due to impaired neural tube 
development (Shim et al., 2005). Thus, in order to study TAK1 in vivo, a number of mice 
strains were generated allowing for conditional MAP3K7 (TAK1) deletion from various 
cell types such as: mouse embryonic fibroblast (MEF) cells, myocardium, hepatocytes, 
intestinal epithelial cells, keratinocytes, cartilage and fibroblast cells (Inokuchi et al., 
2010; Kajino-Sakamoto et al. 2008; Liu et al., 2006; Ma et al., 2011; Omori et al., 2006; 
Sato et al., 2005; Shim et al. 2009; Xie et al., 2006; Zhang et al., 2000; Zheng et al., 
2002). In particular, a fibroblast-specific MAP3K7-KO mouse model may be considered 
for subsequent studies of TAK1-mediated signaling in gingival fibroblasts, wound 
healing functional assessment as well as nifedipine-induced gingival hyperplasia in mice 
as was previously reported using rat models (Kataoka et al., 2001). In the former, 
fibroblast explants from gingiva of control (C57/BL6) as well as fibroblast specific 
TAK1-KO mice may be studied in greater detail in response to TGFβ1 induction or 
mechanical strain in culture, with subsequent analysis of the canonical and non-canonical 
signaling pathways. A similar study has been conducted using an established fibroblast 
specific MAP3K7-KO mouse model where the loss of TAK1 resulted in impaired 
proliferative, adhesive and migratory properties of cultured dermal fibroblasts (Guo et al., 
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2012). Further, the phenotypic differences in gingival tissues of the control and fibroblast 
specific MAP3K7-KO mice may be monitored histologically in response to oral 
administration of nifedipine (Nalini et al., 1990) or in response to the administration of 
other drugs which are known to be associated with gingival hyperplasia induction.  
Compared to studies relying on the genetic knock-out of MAP3K7, studies using a 
small molecule may be better suited for the translational, bench-to-bedside research 
approach. (5Z)-7-Oxozeaenol has been previously administered to mice and rats. A two 
week IP injection of (5Z)-7-Oxozeaenol into female nude mice at 15 mg/kg resulted in 
neuroblastoma sensitization to doxorubicin (Dox) and etoposide (VP-16) 
chemotherapeutic drugs using orthotopic neuroblastoma mouse model (Fan et al., 2013). 
Intracerebroventricular as well as IP injection of (5Z)-7-Oxozeaenol into male mice at 
various doses accounted for a promising neuroprotective therapeutic approach in stroke 
treatment (White et al, 2012).  Further, adult male Sprague–Dawley rats injected 
intracerebroventricularly with (5Z)-7-oxozeaenol exhibited improved neurological 
function and neuronal survival after induced traumatic brain injury (Zhang et al., 2013). 
Unfortunately, studies primarily focusing on the safety of systemic (5Z)-7-oxozeaenol 
administration as well as pharmacokinetic and pharmacodynamic properties still remain 
to be conducted in the future, including pre-clinical trials and Phase I clinical trials in 
humans. Should local application of (5Z)-7-oxozeaenol be considered for gingival 
hyperplasia treatment, the overall effect of this ligand on the oral mucosa and underlining 
tissues as well as the effect on gastrointestinal tract must also be established.  
A number of additional TAK1 inhibitors including Pyrazolo[4,3-c]isoquinolines 
and  5Z-7-oxozeaenol  analogues have been recently identified and may be considered for 
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treatment of gingival hyperplasia and/or study of TAK1-mediated signaling responses 
(Buglio et al., 2012, Lockman et al., 2011, and Mortier et al., 2010). Oral administration 
of TAK1 inhibitors may also be considered in the future where a study using orally 
administered LYTAK1, a small molecule inhibitor of TAK1, showed a reduction of 
TAK1-mediated resistance to chemotherapeutic drugs for pancreatic adenocarcinoma 
treatment in orthotopic nude mouse model (Melisi et al., 2011).  
Collectively, my results suggest that TAK1 mediates the ability of TGFβ1 to 
induce CCN2 expression (mRNA and protein) and transcriptional responses in gingival 
fibroblasts. Notably, TAK1 inhibition blocks the ability of TGFβ1 to elicit proliferative 
responses as well as the expression of wound healing genes in gingival fibroblasts. My 
thesis described data supporting the long-term hypothesis that targeting the non-canonical 
TAK1-mediated TGFβ1 signaling pathway may be useful to combat gingival hyperplasia 
in the future.  
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Supplemental Table 3.3.  List of genes sensitive to TAK1 inhibition with over 1.7 fold 
induction in response to TGFβ-1 treatment (N=2).  
Affymetrix 
ID 
Genbank 
Accession  Gene Name 
Fold 
Increase  
7918857 GU971730 TSPAN2 12.5003 
8067233 AJ308020 PMEPA1 9.40699 
7950933 AB041035 NOX4 8.49418 
8116921 AK291838 EDN1 6.7818 
8109159 ENST00000384967 MIR145 4.99812 
8156919 AK300099 MURC 4.93433 
8112045 AK300634 ESM1 4.31011 
8131600 BC033863 TSPAN13 4.15714 
7970793 AK093932 SLC46A3 4.09995 
8114572 BC033097 HBEGF 4.0607 
7922162 AB209540 SLC19A2 4.05461 
7972750 BC151220 COL4A1 3.80166 
8175261 ENST00000385270 MIR503 3.63312 
7962579 AY454159 AMIGO2 3.45511 
7933075 AF086500 FZD8 3.37736 
8095043 AY839725 RASL11B 3.35287 
7954511 AB023182 STK38L 3.3435 
8008885 ENST00000362134 MIR21 3.25119 
8035517 AK074508 COMP 3.02008 
8088550 AK127113 PRICKLE2 3.00856 
8148304 AF205437 TRIB1 2.96456 
8123936 AK292682 NEDD9 2.93624 
7922328 ENST00000385289 MIR199A2 2.91144 
8023220 AF010193 SMAD7 2.841 
8077490 AF216709 LMCD1 2.81825 
7966026 BC152462 NUAK1 2.68415 
7987315 BC009978 ACTC1 2.64134 
7958352 AK091276 BTBD11 2.63841 
7962689 AF026260 VDR 2.55848 
8160439 ENST00000362307 MIR31 2.53933 
8113504 ENST00000446294 NREP 2.53329 
8115490 AF134707 ADAM19 2.44597 
7900510 AK130549 CTPS1 2.44545 
8161701 AF137030 TMEM2 2.43863 
8023995 AK291958 FSTL3 2.43461 
8056184 AK290300 ITGB6 2.41065 
8147012 BC022265 PKIA 2.41012 
8024485 AF078077 GADD45B 2.39958 
7990873 AB095929 MEX3B 2.38217 
7974335 ENST00000515947 RN5S385 2.38034 
96 
 
Affymetrix 
ID 
Genbank 
Accession  Gene Name 
Fold 
Increase  
8159900 BC033899 GLIS3 2.37678 
8160435 AY358570 IFNE 2.3663 
8143154 AK091081 DGKI 2.34734 
8109157 NR_029684 MIR143 2.33962 
7958202 AB042326 CHST11 2.28914 
8169240 AK297968 PRPS1 2.2807 
8136341 BC017050 BPGM 2.27611 
8151334 BC006313 MSC 2.26058 
8121257 AF084199 PRDM1 2.25456 
7950391 AB019210 PGM2L1 2.25386 
7926545 AF378757 PLXDC2 2.23225 
7933872 AF139463 EGR2 2.22617 
7934434 AF240633 MYOZ1 2.2035 
8135069 AK293248 SERPINE1 2.17387 
7993588 AK094664 TMC7 2.17183 
8112803 BC136335 LHFPL2 2.14818 
7970033 ENST00000400163 COL4A2 2.14259 
8057990 AK301209 ANKRD44 2.13067 
7997642 AK027395 CRISPLD2 2.12702 
7959361 BC151841 MLXIP 2.12286 
8160637 AK297541 B4GALT1 2.12002 
7972557 BC020752 GPR183 2.10273 
8023415 AK299169 TCF4 2.10147 
7923173 ENST00000385240 MIR181B1 2.09207 
8137670 AK292217 PDGFA 2.07886 
8041206 AF110224 LBH 2.07127 
8072678 BC001491 HMOX1 2.05866 
8109426 ENST00000524264 FLJ38109 2.05775 
8022674 BC036470 CDH2 2.04821 
8139207 AK290584 INHBA 2.04306 
8114970 AY358656 C5orf46 2.04245 
7950374 AK300598 P4HA3 1.99257 
7905428 AK299925 TUFT1 1.98978 
8116418 AB016789 GFPT2 1.98967 
7906995 BT006860 UCK2 1.98699 
8111430 EF560721 AMACR 1.97704 
8123104 BC146783 FNDC1 1.9678 
8156571 ENST00000385129 MIR27B 1.96393 
7936322 AL833061 GPAM 1.95685 
7979710 AF228603 PLEK2 1.95078 
7922773 AF527950 NCF2 1.94535 
8162940 AB055982 ABCA1 1.94403 
7965094 BC017481 E2F7 1.93429 
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Affymetrix 
ID 
Genbank 
Accession  Gene Name 
Fold 
Increase  
7991080 AK302992 BNC1 1.93384 
7972239 BC101070 SLITRK6 1.93138 
7922976 AK292167 PTGS2 1.92186 
8063634 BC002831 MGC4294 1.91941 
8021707 BC020082 SOCS6 1.91887 
8094751 BC113549 CHRNA9 1.91164 
8156573 AF480560 MIR24-1 1.91017 
8102232 AF198532 LEF1 1.90975 
7943803 AK055899 DIXDC1 1.90939 
8035896 AK293267 TSHZ3 1.9092 
7953981 AK289441 ETV6 1.90186 
7934997 AK299392 PPP1R3C 1.89232 
8139488 AK298143 IGFBP3 1.88748 
7986789 BC038712 ATP10A 1.88652 
8040473 AF498971 RHOB 1.88318 
7944302 AB094090 PHLDB1 1.87993 
8026047 BC004250 JUNB 1.87672 
7974316 BC020521 FRMD6 1.8761 
8154962 AF088982 DNAJB5 1.87319 
7922889 ENST00000367498 IVNS1ABP 1.87315 
7950555 BC070079 LRRC32 1.86387 
8167013 ENST00000424392 PHF16 1.86357 
8088776 AF146696 FOXP1 1.86169 
8161945 ENST00000376447 RASEF 1.85336 
8121685 AJ420528 DCBLD1 1.85226 
8039484 AK290572 IL11 1.84543 
8005661 AK304186 SPECC1 1.84376 
8109407 AB078145 GALNT10 1.82627 
8060850 ENST00000378827 BMP2 1.81767 
8020455 U66075 GATA6 1.81052 
7909494 BC130323 SYT14 1.80486 
8103695 AK290041 MFAP3L 1.79877 
8095767 AK074237 C4orf26 1.79371 
8026198 ENST00000440752 ZSWIM4 1.79067 
7965112 ENST00000550006 PAWR 1.78964 
7922326 ENST00000385214 MIR3120 1.78538 
8092836 BC031569 CPN2 1.77686 
8054997 AK074577 MAP3K2 1.77627 
8056257 U76833 FAP 1.77509 
7999909 AF181862 GPRC5B 1.76782 
7944722 AF425252 UBASH3B 1.75863 
8157253 ENST00000374232 SNX30 1.75667 
8072705 AF279143 RASD2 1.75216 
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Affymetrix 
ID 
Genbank 
Accession  Gene Name 
Fold 
Increase  
8157802 ENST00000385004 MIR181B2 1.74598 
8142415 AK299901 C7orf60 1.74074 
8058477 AK297312 KLF7 1.73553 
8047738 AL833606 NRP2 1.73487 
8010061 AF200328 SPHK1 1.72518 
8025402 AB056477 ANGPTL4 1.72498 
8151816 BC022010 GEM 1.72429 
7956271 AF016509 HSD17B6 1.7231 
8104035 AK056628 SORBS2 1.72124 
8155192 AK091288 GLIPR2 1.71552 
7943998 BC000234 NNMT 1.711 
7901993 AK299361 CACHD1 1.70334 
8141241 ENST00000361125 SMURF1 1.70312 
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Supplemental Table 3.4.  List of genes with over 1.7 fold induction in response to 
TGFβ-1 treatment (N=2).  
 
Affymetrix 
ID 
Genbank 
Accession  Gene Name 
Fold 
Increase  
7918857 GU971730 TSPAN2 12.5003 
8067233 AJ308020 PMEPA1 9.40699 
7950933 AB041035 NOX4 8.49418 
8116921 AK291838 EDN1 6.7818 
7974689 AF251079 DACT1 5.38907 
8109159 ENST00000384967 MIR145 4.99812 
8156919 AK300099 MURC 4.93433 
8112045 AK300634 ESM1 4.31011 
8131600 BC033863 TSPAN13 4.15714 
7970793 AK093932 SLC46A3 4.09995 
8114572 BC033097 HBEGF 4.0607 
7922162 AB209540 SLC19A2 4.05461 
7972750 BC151220 COL4A1 3.80166 
8175261 ENST00000385270 MIR503 3.63312 
7962579 AY454159 AMIGO2 3.45511 
7933075 AF086500 FZD8 3.37736 
8095043 AY839725 RASL11B 3.35287 
7954511 AB023182 STK38L 3.3435 
8008885 ENST00000362134 MIR21 3.25119 
8035517 AK074508 COMP 3.02008 
8088550 AK127113 PRICKLE2 3.00856 
8083876 AK300053 SKIL 2.96522 
8148304 AF205437 TRIB1 2.96456 
8123936 AK292682 NEDD9 2.93624 
7922328 ENST00000385289 MIR199A2 2.91144 
8023220 AF010193 SMAD7 2.841 
8077490 AF216709 LMCD1 2.81825 
7966026 BC152462 NUAK1 2.68415 
7987315 BC009978 ACTC1 2.64134 
7958352 AK091276 BTBD11 2.63841 
8178435 AF083421 IER3 2.57544 
8129562 AK290884 CTGF 2.55987 
7962689 AF026260 VDR 2.55848 
8160439 ENST00000362307 MIR31 2.53933 
8077441 AB004066 BHLHE40 2.5374 
8113504 ENST00000446294 NREP 2.53329 
8124848 BC005080 IER3 2.51526 
8179704 AF083421 IER3 2.51526 
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Affymetrix 
ID 
Genbank 
Accession  Gene Name 
Fold 
Increase  
8115490 AF134707 ADAM19 2.44597 
7900510 AK130549 CTPS1 2.44545 
8161701 AF137030 TMEM2 2.43863 
8023995 AK291958 FSTL3 2.43461 
8056184 AK290300 ITGB6 2.41065 
8147012 BC022265 PKIA 2.41012 
8024485 AF078077 GADD45B 2.39958 
7990873 AB095929 MEX3B 2.38217 
7974335 ENST00000515947 RN5S385 2.38034 
8159900 BC033899 GLIS3 2.37678 
8160435 AY358570 IFNE 2.3663 
8143154 AK091081 DGKI 2.34734 
8109157 NR_029684 MIR143 2.33962 
7958202 AB042326 CHST11 2.28914 
8169240 AK297968 PRPS1 2.2807 
8136341 BC017050 BPGM 2.27611 
8151334 BC006313 MSC 2.26058 
8121257 AF084199 PRDM1 2.25456 
7950391 AB019210 PGM2L1 2.25386 
7926545 AF378757 PLXDC2 2.23225 
7933872 AF139463 EGR2 2.22617 
7934434 AF240633 MYOZ1 2.2035 
8152215 BT006634 KLF10 2.18971 
8135069 AK293248 SERPINE1 2.17387 
7993588 AK094664 TMC7 2.17183 
8112803 BC136335 LHFPL2 2.14818 
7970033 ENST00000400163 COL4A2 2.14259 
8057990 AK301209 ANKRD44 2.13067 
7997642 AK027395 CRISPLD2 2.12702 
7959361 BC151841 MLXIP 2.12286 
8160637 AK297541 B4GALT1 2.12002 
7972557 BC020752 GPR183 2.10273 
8023415 AK299169 TCF4 2.10147 
7923173 ENST00000385240 MIR181B1 2.09207 
8137670 AK292217 PDGFA 2.07886 
8041206 AF110224 LBH 2.07127 
8072678 BC001491 HMOX1 2.05866 
8109426 ENST00000524264 FLJ38109 2.05775 
8022674 BC036470 CDH2 2.04821 
8139207 AK290584 INHBA 2.04306 
8114970 AY358656 C5orf46 2.04245 
7950374 AK300598 P4HA3 1.99257 
7905428 AK299925 TUFT1 1.98978 
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Affymetrix 
ID 
Genbank 
Accession  Gene Name 
Fold 
Increase  
8116418 AB016789 GFPT2 1.98967 
7906995 BT006860 UCK2 1.98699 
8111430 EF560721 AMACR 1.97704 
8123104 BC146783 FNDC1 1.9678 
8156571 ENST00000385129 MIR27B 1.96393 
7936322 AL833061 GPAM 1.95685 
7979710 AF228603 PLEK2 1.95078 
7922773 AF527950 NCF2 1.94535 
8162940 AB055982 ABCA1 1.94403 
7965094 BC017481 E2F7 1.93429 
7991080 AK302992 BNC1 1.93384 
7972239 BC101070 SLITRK6 1.93138 
7922976 AK292167 PTGS2 1.92186 
8063634 BC002831 MGC4294 1.91941 
8021707 BC020082 SOCS6 1.91887 
8094751 BC113549 CHRNA9 1.91164 
8156573 AF480560 MIR24-1 1.91017 
8102232 AF198532 LEF1 1.90975 
7943803 AK055899 DIXDC1 1.90939 
8035896 AK293267 TSHZ3 1.9092 
7953981 AK289441 ETV6 1.90186 
7934997 AK299392 PPP1R3C 1.89232 
8139488 AK298143 IGFBP3 1.88748 
7986789 BC038712 ATP10A 1.88652 
8040473 AF498971 RHOB 1.88318 
7944302 AB094090 PHLDB1 1.87993 
8026047 BC004250 JUNB 1.87672 
7974316 BC020521 FRMD6 1.8761 
8154962 AF088982 DNAJB5 1.87319 
7922889 ENST00000367498 IVNS1ABP 1.87315 
7950555 BC070079 LRRC32 1.86387 
8167013 ENST00000424392 PHF16 1.86357 
8088776 AF146696 FOXP1 1.86169 
8161945 ENST00000376447 RASEF 1.85336 
8121685 AJ420528 DCBLD1 1.85226 
8039484 AK290572 IL11 1.84543 
8005661 AK304186 SPECC1 1.84376 
8109407 AB078145 GALNT10 1.82627 
8060850 ENST00000378827 BMP2 1.81767 
8020455 U66075 GATA6 1.81052 
7909494 BC130323 SYT14 1.80486 
8103695 AK290041 MFAP3L 1.79877 
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Affymetrix 
ID 
Genbank 
Accession  Gene Name 
Fold 
Increase  
8095767 AK074237 C4orf26 1.79371 
8026198 ENST00000440752 ZSWIM4 1.79067 
7965112 ENST00000550006 PAWR 1.78964 
7922326 ENST00000385214 MIR3120 1.78538 
8092836 BC031569 CPN2 1.77686 
8054997 AK074577 MAP3K2 1.77627 
8056257 U76833 FAP 1.77509 
7999909 AF181862 GPRC5B 1.76782 
7944722 AF425252 UBASH3B 1.75863 
8157253 ENST00000374232 SNX30 1.75667 
8072705 AF279143 RASD2 1.75216 
8157802 ENST00000385004 MIR181B2 1.74598 
8142415 AK299901 C7orf60 1.74074 
8058477 AK297312 KLF7 1.73553 
8047738 AL833606 NRP2 1.73487 
8010061 AF200328 SPHK1 1.72518 
8025402 AB056477 ANGPTL4 1.72498 
8151816 BC022010 GEM 1.72429 
7956271 AF016509 HSD17B6 1.7231 
8104035 AK056628 SORBS2 1.72124 
8155192 AK091288 GLIPR2 1.71552 
7943998 BC000234 NNMT 1.711 
7901993 AK299361 CACHD1 1.70334 
8141241 ENST00000361125 SMURF1 1.70312 
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